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SUMMARY 
 
Sutherlandia frutescens (tribe Galegeae, Fabaceae), is a popular medicinal plant 
traditionally used in South Africa.  In 2000, a company called Phyto Nova (Pty) Ltd. 
initiated large-scale cultivation and contract manufacturing of tablets, made from the 
powdered herb (i.e. thin stems and leaves). Most of these commercial Sutherlandia solid 
dosage forms are made from the dried leaf powder but  recently a new product, viz. 
Promune™ capsules, made from a freeze-dried aqueous extract, came on the market and 
was claimed to be “better” as it mimics the traditional tea.  However, the pharmaceutical 
quality and stability of these preparations have not yet been investigated. 
 
The objectives of this study were firstly, to develop a validated stability-indicating HPLC 
assay for sutherlandioside B (SU-B); secondly, to compare the SU-B levels in the two 
commercially available Sutherlandia products viz, the Phyto Nova Sutherlandia SU1™ 
tablet and the Promune™ capsule, and, thirdly, to determine the effect of elevated 
temperature and humidity as well as acid hydrolysis on the SU-B levels in these two 
products. 
 
To realize these objectives, the major glycoside, sutherlandioside B (SU-B), of the plant 
S. frutescens was firstly extracted with methanol and isolated using silica gel column 
chromatographic fractionation.  Then an HPLC method for its quantification in the plant 
material was developed and validated and, finally,   applied to determine the SU-B levels 
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in these two commercial Sutherlandia products and the effect that elevated temperature, 
humidity and acid hydrolysis have on these SU-B levels.  
 
The cycloartane glycoside, sutherlandioside B was successfully isolated and its 
identification established using a LC-MS method.  A simple, precise reverse phase 
HPLC-UV method that used a reverse phase Discovery® C-18 column, a mixture of 
water/acetonitrile with formic acid as mobile phase and a detection wavelength of 260 
nm were used for the isolation and detection of the SU-B peak.  The developed method 
was highly reproducible and linear over range 22-330μg/ml, with a limits of detection 
(LOD) and limits of quantification (LOQ) of 0.5 and 22μg/ml, respectively. The intra- 
and inter day variation was lower than 3.0% and the within day CVs for the replicates 
(n=6) at two different concentrations (22 and 55 µg) was 1.23%. 
 
The Phyto Nova Sutherlandia SU1™ tablets had a higher average SU-B concentration 
than the Promune™ capsules, i.e.  1.73 ± 0.013 μg/mg versus 1.523 ± 0.016 μg/mg (n 
=6).  The average daily dose of SU-B in the Phyto Nova Sutherlandia SU1™ tablets was 
thus  significantly higher than that in the Promune™ capsules (i.e. 519 μg vs. 137.07 μg, 
respectively, p = ??).  
 
When stored at 400C and 70% relative humidity for four weeks the  SU-B in the Phyto 
Nova Sutherlandia SU1™ tablets, stored  sealed and unsealed, decreased by 38.27% and 
41.68 %, respectively while that in  the Promune™  capsules, stored sealed and unsealed,  
decreased by 34.08% and 35.13% respectively.  
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Collectively, the results of this study indicate that instabilities such as degradation by 
elevated temperature, humidity and acid can be identified using the developed HPLC 
assay and can thus be used to monitor Sutherlandia product stability.  This study also 
provides valuable preliminary data on the stability profile of Sutherlandia tablets and 
capsules using SU-B as marker compound that could be useful for any future quality 
control studies on this medicinal plant. 
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CHAPTER ONE 
INTRODUCTION 
 
Today in South Africa, most of the population in urban, as well as smaller rural 
communities, are still reliant on  medicinal plants for their health care needs (Fennell et 
al., 2004).  One such medicinal plant used in South Africa is Sutherlandia frutescens. 
Traditionally S. frutescens is used for a wide diversity of ailments, among others, the 
treatment of stomach ailments, diabetes, internal cancers, stress, fever and wounds.  
Recently S. frutescens was used as a tonic by AIDS patients, and claimed to result in an 
improvement of mood and appetite, weight gain, improved CD4 counts and reduced viral 
loads (Gericke et al., 2001; Morris, 2001; Chaffy and Stokes, 2002; Van Wyk, 2004). 
 
In recent years Sutherlandia frutescens has received a marked increase in both scientific 
and commercial attention in recent years.   Small-scale cultivation and commercialization 
of Sutherlandia frutescens essentailly started in 1990, when air-dried leaves were 
supplied to a health shop in Port Elizabeth in the Eastern Cape Province.  In2000 a 
company called Phyto Nova (Pty) Ltd. initiated large-scale cultivation and contract 
manufacturing of tablets made from powdered herb (i.e. thin stems and leaves).  Several 
Sutherlandia preparations, made from different raw plant material, are now commercially 
available in South Africa.  These commercially available Sutherlandia preparations are 
found in various dosage forms including tablets, capsules, traditional tea, gel and aqueous 
infusion or decoction.  The pharmaceutical quality of these preparations has however, not 
yet been investigated and they are not registered with the South African regulatory 
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authority, viz. the Medicine Control Council (MCC).  In fact, these medicines cannot be 
registered with the MCC, since the latter at present, do not have the appropriate 
regulations, guidelines, approval and review procedures and product specification 
guidelines in place that can be applied for such herbal product registration.  In particular, 
there are no guidelines and set protocols for the determination of the stability and expiry 
dates of these products. 
 
Most of the currently available solid dose (i.e. capsule or tablet) dosage forms of 
Sutherlandia (e.g. Phyto Nova Sutherlandia SU1™) contain the dried leaf powder  as the 
active plant raw material.  Recently a preparation, viz Promune™, containing the dried 
aqueous extract of Sutherlandia, became commercially available in capsule form.  In the 
package insert for this product, it is claimed that it is closer to the traditional dosage form 
of the plant and thus “better”.  However, it is not really clear how this product compares 
in terms of chemical composition, efficacy and in vivo bioavailability of its active 
constituents, with the equivalent capsule(s) containing the dried leaf powder. 
 
Indeed a full pharmaceutical evaluation of both these preparations, i.e. those containing 
the dry leaf powder or aqueous extract of the plant, need to be done.  In particular, it is 
unclear if or how the stability (and hence the expiry date) of these preparations are 
established.  Moreover, there appears to be no product stability data available to ascertain 
whether the assigned expiry dates are accurate, and, therefore, the absolute quality of 
these medicinal preparations are unknown. 
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To establish the stability of the commercially available Sutherlandia capsules and tablets 
the availability of a stability- indicating assay for a suitable marker compound(s) in the 
Sutherlandia products is essential.  It is known that S. frutescens contains canavanine, 
GABA, flavanoids and saponins, which may be responsible for some of the plants actions 
(Tai et al., 2004), but little information is available on the pharmacodynamic (esp. 
mechanism of action) and pharmacokinetic properties of the active constituents in these 
plant preparations.  Scientifically, it could be assumed that the activities of the plant are 
due to the bio-active ingredients it contains (Muganga, 2004) and its constituents.  
Saponins in particular, could thus contribute to the activity, and therefore serve as 
biomarker for the characterization of the plant raw material and the assessment of the 
quality of these Sutherlandia preparations.   
 
Saponins are glycosides of 27-carbon atom steroids or 30-carbon atom triterpens.  
Triterpene compounds are arranged in a 4-5 ring configuration of 30 carbons with several 
oxygens attached.  Saponins are characterized by its bitter taste and ability to hemolyze 
red blood cells. The saponins in S. frutescens could be responsible for the plants 
immunomodulatory effect, which is evident in its use in HIV/ AIDS, TB and cancer 
patients.  Furthermore, the use of Sutherlandia for hot flushes and irritability in 
menopause could be due to the production of the synthetic hormone progesterone after 
chemical degradation of saponins (Klein, 2004; Attele et al., 1999; Lee et al., 2003).  
Triterpene glycosides were first detected in Sutherlandia microphylla leaves by 
Brűmmerhof (1969) and Viljoen (1969) but the chemical structures were not determined.  
Gabrielse (1996) isolated a pure compound ( later called SU1 or sutherlandioside B) from 
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extracts of Sutherlandia frutescens.  Moshe (1998) reported a complex pattern of 
triterpenes in the various species and forms of Sutherlandia, with limited variation within 
populations but large differences between populations. Recently, four new cycloartane 
glycosides, sutherlandiosides A, B, C and D were isolated from the medicinal plant, S. 
frutescens (Fu et al., 2008).  These compounds, in particular the major glycoside, 
Sutherlandioside B, may serve as chemical markers for the commercial dietary 
supplements prepared from this herbal medicine.   
 
Triterpenoids, more specifically, Sutherlandioside B (or SU1), the major cycloartane 
triterpene glycoside of the plant S. frutescens can be assayed using gas chromatography 
(GC), high performance liquid chromatography (HPLC) and thin layer chromatography 
(TLC).  HPLC is the method of choice for the analysis, because of its versatility, 
precision, high speed separation and sensitivity to low concentrations and relatively low 
cost.  This technique, coupled with various detectors (e.g. diodide array, UV and ELSD 
detectors and Mass spectrometer) provides specificity in detection and compatibility with 
a wide range of organic solvents miscible with water, which should ease any solubility 
problems with the saponins.  In addition, HPLC offers advantages of high reproducibility 
and repeatability of data, thus leading to reliable results.  HPLC would thus be an 
imminently suitable method to employ as a stability indicating assay for the major 
glycoside, sutherlandioside B in commercially available Sutherlandia plant materials.  It 
will also be used to ascertain whether monitoring of SU B levels can be used to establish 
the relative pharmaceutical quality of commercially available solid oral dosage forms of 
Sutherlandia. 
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Given the above arguments, the objectives of this study were to:  
1.  develop a validated stability-indicating assay for the determination of 
sutherlandioside B in S. frutescens plant material and products,  
2.  identify and quantify the levels of sutherlandioside B present in commercially 
available products and 
3. compare the effect of elevated temperature and environmental humidity as well as 
acid hydrolysis on the levels and profiles of sutherlandioside B in the Promune™ 
capsules, versus that in the Phyto Nova Sutherlandia SU1™ tablets. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Introduction 
In this chapter an overview is presented of the medicinal plant, Sutherlandia frutescens, 
and its uses, pharmacology, toxicology and chemistry are reviewed. In particular, 
saponins and triterpenoid saponins and more specifically the cyclo-artane glycoside, 
sutherlandioside B, which could be used as marker compound for the characterization 
and the determination of the pharmaceutical quality of these commercially available 
preparations, are discussed.  In addition the merits of analytical methods suitable for 
sutherlandioside analysis such as High Performance Liquid Chromatography (HPLC), 
Thin Layer Chromatography (TLC), LC-MS coupled with UV, IR, diodide array and 
ELSD detectors are reviewed.  The two commercially available Sutherlandia products, 
chosen upon, as well as the effect of elevated temperature, humidity and acid hydrolysis 
on the SU-B levels in these products are discussed. 
 
2.2 Medicinal plants 
Medicinal plants are plants in which one or more of its parts contain substances that can 
be used for therapeutic purposes, or which is a precursor for the synthesis of a direct 
therapeutic agent.  Medicinal plant products in various forms have for many years been 
available to treat disease in both developing and developed countries, and are an 
important part of the culture and tradition of African people.  Besides their cultural 
significance, medicinal plants are more accessible and affordable (Fennel et al., 2004). 
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Presently, the quantity and quality of data on the safety and efficacy of traditional 
medicines are far from sufficient to meet the criteria needed to support their use 
worldwide. Therefore, with the recent advancement in research technology, the 
evaluation of these medicinal plants is therefore a necessity.   
 
One very popular medicinal plant, indigenous to South Africa, and one in which there is a 
marked increase in use, especially commercial use, and where there is a lack of 
appropriate scientifically based information on its pharmaceutical quality, is evident in 
Sutherlandia frutescens. 
 
 
2.3 Taxonomy of Sutherlandia frutescens 
2.3.1    Vernacular names and nomenclature  
Sutherlandia frutescens is one of the best known medicinal plants in the echnobotanical 
world, and it is still used today in South Africa by people of different cultures.  It is 
popularly known as cancer bush, Sutherlandia, balloon pea, and turkey flower (English), 
“umnwele, insiswa” (Xhosa and Zulu), “musa-pelo, musa-pelo-oa-nòka, motlepelo 
(Sesotho) and “kankerbossie, gansies, grootgansies, wildekeur(tjie), keurtjie, 
kalkoen(tjie)bos, kalkoenblom, belbos, kalkoenbelletjie, klapperbos, jantjie-bêrend, 
bitterbos,  eendjies, hoenderbelletjie” (Afrikaans).  Sutherlandia frutescens belongs to: 
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• Division : Magnoliphyta 
• Class  : Magnoliopsida 
• Order  : Fabales 
• Family  : Fabaceae 
• Subfamily : Faboideae 
• Tribe  : Galegeae 
• Genus  : Sutherlandia  and 
• Species : S. frutescens 
(Van Wyk, and Gericke, 2000) 
 
 
2.3.2  Botanical description and distribution 
 
The genus Sutherlandia is so closely related to Lessertia that some botanists consider that 
it should be sunk in to Lessertia (Goldblatt and Manning, 2000). This species is 
sometimes called Lessertia frutescens.  The genus Sutherlandia was named after James 
Sutherland, in the 1639- 1719, first superintendent of the Edinburgh Botanic Garden.  
The genus Lessertia is named after Jules Paul Benjamin de Lessert, 1773- 1847, a French 
industrialist, banker, amateur botanist and owner of an important private herbarium used 
by De Candolle.  The species name frutescens means bushy in Latin.  Sutherlandia 
frutescens is an attractive small, soft wooded shrublet, 0.5 to 1 m in height.  The leaves 
are pinnately compound.  The leaflets are 4-10 mm long, grey-green in colour, giving the 
bush a silvery appearance and have a very bitter taste.  The flowers are orange–red, up to 
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35 mm long and are carried in short racemes in the leaf axils at the tips of the branches in 
spring to mid-summer (September- December).  The wing petals are very small and are 
concealed in the calyx and the standard petal is much shorter than the keel.  The flowers 
are not typical “pea” flowers.  Lastly, the fruit is a large, bladder-like, papery inflated pod 
and is almost transparent (Van Wyk and Gericke, 2000). 
 
Sutherlandia frutescens occurs naturally throughout the dry parts of South Africa, in the 
Western Cape and up the west coast as far north as Namibia and into Botswana, and in 
the western Karoo to Eastern Cape.  It shows remarkable variation within its distribution 
(Van Wyk and Gericke, 2002).  Sutherlandia can have significant biological effects that 
may be useful or harmful. 
 
 
2.4 Pharmacological properties and toxicology of Sutherlandia frutescens 
Sutherlandia frutescens is one of the most talked about plants in the ethno-botanical 
world, because of its strong reputation as a cure for cancer, and now increasingly, as an 
immune booster in the treatment of HIV/AIDS.  Research on its properties is ongoing.  It 
is known as a “cure all” remedy because of its use to treat a wide range of ailments.  
Traditionally it was used mainly as a decoction for the washing of wounds, bathing of the 
eyes to treat eye troubles and internally to bring down fever.  It is also used to treat 
internal cancers, diabetes mellitus, respiratory disorders such as colds, flu, asthma, 
bronchitis, anti-inflammatory disorders such as rheumatism, rheumatoid and osteo-
arthritis, gastro-intestinal conditions such as diarrhoea, dysentery, stomach ailments, 
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heartburn and peptic ulcers.  Additionally, it is used in the treatment of mental and 
emotional stress, including irritability, anxiety and depression and as a gentle 
tranquillizer.  It is also used as a bitter tonic to aid digestion and to improve appetite (Van 
Wyk and Gericke, 2000; Roberts, 1990).  S.frutescens has become widely known as 
cancer bush, because of the reported use by Khoi-San and Cape Dutch people against 
internal cancers.  Below follows a more detailed discussion on the most common uses of 
Sutherlandia for cancer, HIV/AIDS, diabetes, inflammation, pain and wounds and stress. 
 
2.4.1  Cancer 
Anecdotal evidence exists of cancer patients who experienced an improved quality of life 
and survived for much longer than expected after treatment with Sutherlandia (Van Wyk 
et al., 2000; C. Albrecht, 2008).  Clinical evidence for the reduction of fatigue in cancer 
patients was presented by Grandi et al., (2005).  It can be assumed that the anticancer 
activity of the plant is due to its chemical constituents.  One such chemical constituent of 
the plant S. frutescens is the major leaf metabolite, canavanine (known for its anti-cancer 
activity).  Therefore, the discovery of canavanine in S. frutescens seems to be more than a 
coincidence, although concentrations required for cancer cell kill in vivo would also be 
toxic and no toxicity was found (Seier et al., 2002).  It was also suggested that 
canavanine may play a role in the antiproliferative effects, but that some other factors 
must also be involved, because addition of arginine (antidote for canavanine) did not 
abrogate the antiproliferative effect.  In addition, it is also known that the major 
triterpenoids, sutherlandioside B, of the plant Sutherlandia frutescens are structurally 
closely related to cyclo-artane type triterpenoids that have proven cancer chemo 
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preventive activity (Kikuchi et al., 2007).  Tai et al., (2004) using ethanolic extracts, 
provided the first in vitro evidence of anti-cancer effects by showing a concentration 
dependent 50% inhibition of proliferation of MCF7, MDA-MB-468, Jurkat and HL60 
cells.  Na et al., (2004) reported that methanol extracts of Sutherlandia inhibited the 
DNA binding of NF-κB activated by 12-O-tetradecanoylphorbol-13-acetate (TPA) in 
MCF10A human breast epithelial cells in a dose-dependent manner.  They concluded that 
the inhibition of TPA-induced COX-2 expression through suppression of DNA binding 
of NF-κB may contribute to chemo preventive or chemo protective activity in 
Sutherlandia.  Chinkwo (2005) demonstrated that aqueous whole plant extracts induced 
apoptosis in neoplastic cells, notably cervical carcinoma and CHO (Chinese Hamster 
Ovary cells) cell lines.  The possibility that canavanine is not the only active compound is 
supported by Kikuchi et al., (2007), who studied the cancer chemo preventive activity of 
48 natural and semi-synthetic cyclo-artane type triterpenoids.  Many of the compounds 
(so-called astragalosides) are known from the genus Astragalus L., also a member of the 
tribe Galegeae and related to Sutherlandia.  The most powerful inhibitory effects in an in 
vivo mouse skin carcinogenesis were found in cycloartanes with hydroxylation at C-24 
and with a 3-oxo group.  This configuration is present in SU1 or sutherlandioside B, the 
main cyclo-artane of the commercial type of Sutherlandia (Van Wyk et al., 2007) and 
could be responsible with canavanine for the plants anticancer activity. 
 
2.4.2  HIV and AIDS 
Sutherlandia tablets, used as a tonic by AIDS patients, resulted in an improvement of 
mood and appetite, weight gain, improved CD4 counts and reduced viral loads (Gericke 
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et al., 2001; Morris, 2001; Chaffy and Stokes, 2002; Van Wyk, 2004).  These claims 
have led to a NIH NCAM-sponsored clinical study to evaluate the possible effects of 
Sutherlandia on cachexia (the muscle-wasting effects seen in patients with cancer, 
tuberculosis and AIDS).  A phase 1 study has shown that Sutherlandia is well tolerated 
and that it showed no significant side effects (Johnson et al., 2007).  A phase 2 study is 
said to be currently underway.  It has been speculated that Sutherlandia triterpenoids 
might have cortimimetic activity besides the anticipated bitter tonic (amara) effect (Van 
Wyk and Wink, 2004).  In vitro experiments of the effects of organic and aqueous 
extracts of Sutherlandia on HIV target enzymes (including HIV reverse transcriptase) by 
Harnett et al., (2005) and Bessong et al., (2006) showed that there are some compounds 
in aqueous extracts responsible for inhibitory effects.  Canavanine is an inhibitor of nitric 
oxide synthase and has potential for the treatment of septic shock (Anfossi et al., 1999; 
Levy et al., 1999), a condition associated with advanced stages of AIDS.  The lack of 
inhibition of nitric oxide secretion is concentration related (Tai et al., 2004).  In a review 
of available evidence for the value of Hypoxis and Sutherlandia in treating HIV, Mills et 
al., (2005) noted the absence of clinical trials and warned against possible interactions 
with antiretroviral drugs. 
2.4.3  Diabetes 
Moshe (1998) and Van Wyk et al., (2000) proposed that the high levels of pinitol in 
Sutherlandia leaves as a plausible rationale behind the traditional anti-diabetic use.  A 
review of the limited available pharmacological evidence was presented by Sias (2004), 
who argued that L-canavanine, other amino acids such as L-arginine and pinitol may 
contribute to anti-diabetic effects, either directly or via anti-inflammatory and nitric oxide 
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-inhibitory activity.  The anti-inflammatory and nitric oxide -inhibitory activity of 
Sutherlandia extracts could counteract the insulitis of autoimmune diabetes by protecting 
pancreatic beta-cells against reactive oxygen radicals of which nitric oxide could be one  
Bates et al., (2000) have shown that pinitol exert an insulin-like effect by reducing blood 
sugar levels in diabetic mice, however a preliminary study of the clinical benefits of 
pinitol in obese and mild type 2 diabetic individuals showed disappointing results (Davies 
et al., 2000).  Ojewole (2004) presented evidence that Sutherlandia extracts can reduce 
glucose uptake in STZ-treated mice.  Chadwick et al. (2007) showed statistically 
significant increases in glucose uptake and no weight gain in pre-diabetic rats receiving 
Sutherlandia via their drinking water.   
2.4.4  Inflammation, pain and wounds 
Recent studies have indicated that Sutherlandia extracts have anti-inflammatory, 
analgesic and antibacterial activity.  Kundu et al., (2005) demonstrated in vivo inhibition 
of the expression of cyclooxygase-2 (COX-2).  Tai et al., (2004) did not see significant 
antioxidant effects but Ojewole (2004) recorded statistically significant anti-
inflammatory effects in reducing fresh egg albumin-induced pedal oedema in mice.  
There is a link between antioxidant and anti-inflammatory activities as demonstrated by 
Fernandes et al., (2004), where a hot water Sutherlandia extract had superoxide and 
hydrogen peroxide scavenging activities at concentrations as low as 10 µg/ml.  Katerere 
and Eloff (2005) were the first to report antibacterial activity (of hexane extract) against 
S.aureus, S.faecalis and E.coli at MIC values of 0.31, 1.25 and 2.50 mg/ml, respectively. 
The earliest recorded uses of Sutherlandia refer to the treatment of eye ailments. 
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2.4.5 Stress 
The Zulu name insiswa (“the one which dispels darkness”) and the Tswana name phetola 
(“it changes”) both alludes to the reversal of stress-related conditions.  Sia, (2004) and 
Tai et al., (2004) suggested that GABA may play a role in the improvement of mood of 
patients with chronic ailments.  Prevoo et al. (2008) showed that Sutherlandia attenuates 
adrenal P450 enzymes, which may indicate a possible mechanism by which 
glucocorticoid levels (and symptoms of stress) are reduced. 
 
2.4.6 Other indications 
Ojewole (2008) studied an as yet unrecorded and unpublished traditional use for 
Sutherlandia, namely the treatment of childhood seizures and epilepsy.  In vivo studies 
indicated that Sutherlandia frutescens aqueous leaf extracts displayed antithrombotic 
activity, with an IC50 value of 2.17 mg/ml. 
 
2.4.7 Toxicology 
Sutherlandia has a long history of traditional use, with no reports of any serious side 
effects, suggesting that it can be considered as generally safe.  Mills et al., (2005) 
recorded side effects as dryness of mouth, occasional mild diarrhoea or mild diuresis and 
dizziness in cachectic patients.  Infusions or decoctions of 2.5 to 5 g of dry material per 
day can be regarded as the traditional dose (Van Wyk et al., 1997).  For commercial 
preparations, 300mg of dried leaves twice daily (i.e. 600mg per day) is recommended 
(with the usual precaution that it should be avoided during pregnancy or lactation).  A 
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phase 1 clinical study of 25 healthy adults at Karl Bremer Hospital, Bellville, South 
Africa (Johnson et al., 2007) has shown that two 400mg leaf powder capsules (800mg per 
day) was well tolerated, with no side effects noted during or after the three months trial 
period.  There was no change in frequency of adverse events, nor any clinically 
significant changes in most physical, vital, blood and biomarker indices.  It is possible 
that products, containing Sutherlandia, may interact with antiretroviral medication (Mills 
et al., 2005) or with insulin or other diabetes medication (Sia, 2004).  
 
 
2.5  Chemistry 
It is known that Sutherlandia frutescens contains canavanine, GABA, Pinitol, flavanoids 
and saponins, which may be responsible for some of the plants activity.  
 
2.5.1  Free amino acids 
In common with many members of the family Fabaceae, the leaves of Sutherlandia 
contain high levels of free and protein-bound amino acids, (Moshe, 1998; Van Wyk  
et al., 2000) making it a valuable and palatable fodder plant.  The commercial 
Sutherlandia (the so-called Phyto Nova™ Su-1 type) showed high levels of the free 
amino acids asparagines (1.6-35.0 mg/g), proline (0.7-7.5 mg/g) and arginine (0.5-6.7 
mg/g).  The presence of L-arginine is particularly interesting as this compound is an 
antagonist of L-canavanine that attenuates its anti-proliferative activity (Van Wyk and 
Albrecht, 2007). 
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2.5.2  Non-protein amino acids 
Non-protein amino acids are commonly found in the seeds of Fabaceae.  One of the most 
common compounds is L-canavanine, a seed metabolite recorded from many members of 
the legume family (e.g. Lucerne or alfalfa, Medicago sativa L.).  The discovery of high 
levels of canavanine in Sutherlandia leaves by Moshe (1998) was therefore of 
considerable interest (Van Wyk et al., 1997), and  not only gave some explanation for the 
traditional use of Sutherlandia against cancer, but it also appeared to be the first known 
case of a canavanine-containing plant having a well-recorded history of use against 
cancer.  The level of canavanine in leaves from different species and populations of 
Sutherlandia was found to be very varied, from 0.42mg per g to 14.5mg per g (Moshe, 
1998) and about 1.3-3.1 mg/g in commercial Sutherlandia (SU-1type).  Analysis of the 
same type of Sutherlandia by Tai et al., (2004) confirmed the presence of canavanine in 
commercial material and recorded a level of 3 mg/g dry weight.  
 
Canavanine has documented anticancer (Crooks and Rosenthal, 1994; Swaffar, 1995; 
Rosenthal, 1997; Bence et al., 2002) and antiviral activity, including inhibition of 
influenza virus and retroviruses (Green, 1988). 
 
2.5.3  GABA 
The presence of γ-aminonutyric acid (GABA) may also be relevant, as commercial 
samples contain 0.23-0.85 mg/g (Van Wyk et al., 2007).  GABA is an inhibitory 
neurotransmitter that could partly account for the use of Sutherlandia to treat anxiety and 
stress.  It has also been found to inhibit tumour cell migration (Ortega, 2003). 
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2.5.4  Pinitol 
Early studies by Snyder (1965), Viljoen (1969) and Brűmmerhof (1969) showed the 
presence of the cyclitol called ino-inicytol (also commonly known as pinitol) in 
Sutherlandia microphylla leaves.  Using pure pinitol as a reference standard in HPLC 
analysis, with a refractive index detector, Moshe (1998) reported a level of up to 14mg/g 
dry weight in the leaves.  The recorded bioactivities of pinitol make it a potentially 
important compound in the context of the traditional uses of Sutherlandia against 
diabetes and inflammation.  Pinitol is a known anti-diabetic agent that may have an 
application in treating wasting in cancer and AIDS (Ostlund and Sherman, 1996).  It 
exerts an insulin-like effect, resulting in lower blood sugar levels and increased 
availability of glucose for cell metabolism (Bates et al., 2000) and augments the retention 
of creatinine by muscle cells (Greenwood et al., 2001).  Pinitol therefore seems to play a 
role in regulating cellular energy, resulting in increased energy levels, and a reduction in 
fatigue. 
 
 
 
2.5.5  Flavanoids 
Sutherlandia leaves are known to contain at least six flavanoids (Moshe, 1998; Fu et al., 
2009).  Preliminary structural elucidation has indicated that these are flavonol glycosides 
(Van Wyk et al., 2007).   
 
 
 
 
 
18 
 
2.5.6  Saponins 
Saponins are the glycosides of 27 carbon atom steroids, or 30 carbon atom triterpenes.   
They are found in various parts of the plant: leaves, stems, roots, bulbs, blossom and 
fruit.  Saponins dissolve in water to form a stable soapy froth due to its amphiphilic 
nature, hence c the name sapon, which means “soap”.  They are also characterized by 
their bitter taste and its ability to haemolyse red blood cells.  The removal of the sugar 
moiety (hexoses, pentoses and saccharic acids) from a saponin by complete hydrolysis 
yields the aglycone, sapogenin.  Saponins are highly toxic to cold-blooded animals, due 
to their ability to lower surface tension.  Saponins as the sapogenin aglycone have also 
been identified in the animal kingdom in snake venom, starfish and sea cucumber             
(Sahelian, 2007; Dharmananda, 2000). 
 
Triterpenes belong to a large group of compounds arranged in four or five ring 
configurations of 30 carbons with several oxygen’s attached.  Triterpenes are assembled 
from a C5 isoprene unit through the cytosolic mevalonate pathway to make a C30 
compound that is steroidal in nature.  Cholesterol is one example of a triterpene as well as 
phytosterols and phytoecdysteroids.  Triterpenes are responsible for the adaptogenic 
effect found in plants such as Panax ginseng or Eleutherococcus senticosus.  Most 
triterpenoid compounds in adaptogenic plants are found as saponin glycosides, which 
refer to the attachment of various sugar molecules to the triterpene unit.  The sugars can 
be easily cleaved off in the gut by bacteria, allowing the aglycone (triterpene) to be 
absorbed, that allow them insert into cell membranes and modify the composition, 
membrane fluidity and potentially affect signalling by many ligands and cofactors      
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(Klein, 2004; Attele et al., 1999; Lee et al., 2003).  Triterpenoid saponins are mild 
detergents and used to permeabilize the plasma membrane, as well as the membranes of 
internal organelles such as ER and Golgi, but do not penetrate the nuclear membrane.  
Therefore, it is used in intracellular histochemistry staining to allow antibody access to 
intracellular proteins.  Saponins have hypercholestrolaemia, hyperglycaemia, antioxidant, 
anti-cancer, anti-inflammatory and weight loss activity (Sahelian, 2007; Desert King 
Chile, 2007).   
 
 Triterpene saponins are designated as such by the suffix ending-side, such as 
ginsenoside, astragaloside, named for the plant genera they were first discovered in. 
Diosgenin, a steroid sapogenin is a product of hydrolysis by acids, strong bases or 
enzymes of saponins, extracted from the tubers of Dioscorea wild yam.  The sugar-free, 
aglycone, diosgenin is used for the commercial synthesis of progesterone, cortisone and 
other steroid products where as the unmodified steroid has estrogenic activity and can 
reduce the level of serum cholesterol.  The steroid-like saponins in Wild yam can be 
chemically converted to progesterone contraceptives and cortisone.  Ginsenosides are a 
class of steroid-like triterpene saponins, found exclusively in the plant genus Panax 
(ginseng).  Ginsenosides are viewed as the active compounds behind the claims of 
ginseng’s efficacy (Sahelian, 2007; Desert King Chile, 2007).   
 
 
Triterpene glycosides were first detected in Sutherlandia microphylla leaves by 
Brűmmerhof (1969) and Viljoen (1969), but the chemical structures were not determined.  
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Gabrielse (1996) isolated a pure compound (later called SU1) from extracts of 
Sutherlandia frutescens (S. microphylla).  Moshe (1998) reported a complex pattern of 
triterpenes in the various species and forms of Sutherlandia, with limited variation within 
populations, but large differences between populations. Phytochemical investigation of S. 
frutescens led to the identification of one secocyclo-artanol glycoside (sutherlandiosides 
A) and three cycloartanol glycosides (sutherlandioside B, C and D), but the effect of 
these saponins is still unknown (Fu et al., 2008). Sutherlandioside B, C and D are the first 
examples of naturally occurring cycloartanes with a C-1 ketene function.  The major 
triterpene in commercial Sutherlandia material is a cycloartane-type triterpene glycoside 
called SU1 or sutherlandioside B (Fu et al., 2008). 
 
Sutherlandioside B could be used as a potential marker for the evaluation of 
pharmaceutical quality (shelf-life, stability) of commercially available S. frutescens 
preparation.   Sutherlandioside B is the major glycoside and most abundant in the plant 
and was obtained as colourless needles from methanol in a yield of 1.95% (Fu et al, 
2007). Sutherlandioside B (SU1) is a cycloartane-type triterpene glycoside with a 
molecular formula as C36H60O10 and the structure is defined as 3α,7β,24S,25-
tetrahydroxycycloartan-1-one 25-O-β-D-glucopyranoside (Fu et al, 2007).  At least 56 
different triterpene glycosides have been detected in various provenances of 
Sutherlandia.  The mixture of cycloartane-type triterpenoid glycosides also varies 
geographically in South Africa (Olivier et al, 2008 C. Albrecht, 2008).  The chemical 
structure of the major cycloartane glycoside, sutherlandioside B can be seen in figure 
one.   
 
 
 
 
21 
 
 
 
 
Figure 1: Chemical structure of sutherlandioside B 
 
Sutherlandioside B proves to be a possible marker for the determination of the 
pharmaceutical quality of Sutherlandia product.  However, a suitable analytical method 
for the determination of SU-B levels in these products is required.   
 
2.6  Analytical methods suitable for sutherlandioside analysis 
Saponins are very challenging to analyze because of their reactivity.  However, various 
solvents, such as alcohols (i.e. methanol) and organic solvents such as chloroform or 
hexane, are commonly used to extract the aglycone form of saponins.   
 
The complete analysis of the absolute structure and configuration of saponins is usually a 
complicated task, which requires the application of advanced techniques such as Nuclear 
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magnetic Resonance (NMR) spectroscopy, X-ray diffraction, optical rotary dispersion 
and mass spectrophotometry.  Since only a few laboratories are equipped and staffed to 
make all these expensive methods available, simpler approaches to saponins 
characterization are often desired.  Therefore, modern chromatographic techniques such 
as Thin Layer Chromatography and High Performance Liquid chromatography (HPLC) 
are often used.  Some of these techniques are normally coupled with different detectors 
including the fluorescens, UVspectro-photometry (i.e. most commonly use), photo 
diodide array and evaporative light scattering (ELSD) (Havsteen, 2002; Hollman and 
Katan, 1999).  
 
The HPLC is the mostly commonly used method, and has become the standard 
equipment for analysis of saponins.  It yields excellent resolution and retention times that 
are extremely reliable in identification of saponins.  It has several advantages such as 
simplicity, sensitivity, specificity and better separation when using smaller sample 
quantities.  More specifically Reverse-Phase HPLC is the most commonly used form of 
HPLC. 
In reverse phase HPLC, the column size is the same, but the silica is modified to make it 
non-polar by attaching long hydrocarbon chains to its surface - typically with either 8 or 
18 carbon atoms in them. A polar solvent is used - for example, a mixture of water and an 
alcohol such as methanol.  There will be a strong attraction between the polar solvent and 
polar molecules in the mixture being passed through the column. There will not be as 
much attraction between the hydrocarbon chains attached to the silica (the stationary 
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phase) and the polar molecules in the solution. Polar molecules in the mixture will 
therefore spend most of their time moving with the solvent.  However, the non-polar 
compounds in the mixture will tend to form attractions with the hydrocarbon groups 
because of Van der Waals dispersion forces. They will also be less soluble in the solvent, 
because of the need to break hydrogen bonds.  They therefore spend less time in solution 
in the solvent and this will slow them down on their way through the column.  The 
addition of pH modifiers such as acetic acid or formic acid are normally used to reduce 
the presence of the ionized form, thus improving the retention time (Muganga, 2004).  
Therefore, the availability and sensitivity of these analytical methods provide the 
possibility of developing a stability-indicating HPLC assay.  Figure two presents a flow 
schematic representation of a HPLC system starting from sample injection through to the 
processing and the display of the signal. 
 
 
 
 Figure 2: A flow scheme for HPLC 
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During the HPLC method development, it was noted that, for the determination of 
saponins and triterpenoids, a reverse phase HPLC method, with a  evaporative light 
scattering detector (ELSD), is usually employed, because the ELSD response does not 
depend on the samples optical characteristics and is capable of detecting most non-
volatile compounds (Vervoort et al., 2008).  As a result, it has been successfully applied 
to the analysis of these compounds such as sugars, saponins (Wei et al., 2007; Wang et 
al., 2007), fatty acid esters and steroidal alkaloids.  A C18 column is usually employed as 
stationary phase with a mobile phase of acetonitrile- aqueous phase, with a 0.1% acetic 
acid or formic acid as buffer.  The sutherlandiosides are structurally very closely related 
and very challenging to separate and to detect, because of their low UV absorption.  The 
unavailability of an ELSD detector forced us to develop a HPLC assay, coupled with a 
UV diodide array detector, which is still sensitive enough to detect low levels of the 
major cyclo-artane glycoside, SU B.   
2.7  Validation of analytical procedures in this case, a stability-indicating HPLC  
            method 
Method validation is regarded as the process of providing documented evidence that the 
method does what it is intended to do.  Method validation provides an assurance of 
reliability during normal use.  The validation of analytical procedures is directed to the 
four most common types of analytical procedures, viz. the identification test, quantitative 
test for impurities contest, limit tests for the control of impurities and the quantitative 
tests of the active moiety in samples of drug substance or drug product or other selected 
component(s) in the drug product.  Identification tests are intended to ensure the identity 
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of an analyte in a sample.  This is normally achieved by comparison of a property of the 
sample (e.g. spectrum, chromatographic behaviour, chemical reactivity, etc) to that of a 
reference standard.  Testing for impurities can be either a quantitative test or a limit test 
for the impurity in a sample.  Either test is intended to accurately reflect the purity 
characteristics of the sample.  Different validation characteristics are required for a 
quantitative test than for a limit test.  Assay procedures are intended to measure the 
analyte present in a given sample.  Typical validation characteristics which should be 
considered are; accuracy, precision, repeatability, intermediate precision, specificity, 
detection limit, linearity and range.  The quality of analytical data is a key factor in the 
success of a drug development program, thus the process of method development and 
validation has a direct impact on the quality of these data.    
 
2.7.1  Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components (including impurities, degradants and matrix) which may be expected to be 
present.  It is a measure of the degree of interference from such things as other active 
ingredients, excipients, impurities and degradation products, ensuring that a peak 
response is due to a single component only (i.e. that no co-elutions exist).  An 
investigation of specificity should be conducted during the validation of identification 
tests and the determination of impurities and the assay (content or potency).  For 
identification purposes, specificity is demonstrated by the ability to discriminate between 
compounds of closely related structures, or by comparison to known reference materials 
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and for assay and impurity tests, it is demonstrated by the resolution of the two closest 
eluting compounds.  These compounds are usually the major component or active 
ingredient and an impurity.  
2.7.2  Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between 
the value, which is accepted either as a conventional true value or an accepted reference 
value and the value found.  Accuracy is also termed trueness.  The accuracy can be 
established by the application of an analytical procedure to an analyte of known purity                        
(e.g. reference material), by comparing the results of the proposed analytical procedure 
with those of a second well-characterized procedure, the accuracy of which is stated or 
defined and can be inferred once precision, linearity and specificity have been 
established.  It should be assessed by using a minimum of 9 determinations over a 
minimum of 3 concentration levels covering the specified range (e.g. 3 concentrations/ 3 
replicates each of the total analytical procedure).  Accuracy should be reported by the 
assay of known added amount of analyte in the sample or as the difference between the 
mean and the accepted true value together with the confidence intervals. 
2.7.3  Repeatability 
Repeatability expresses the precision under the same operating conditions over a short 
interval of time.  Repeatability is also termed intra-assay precision and should be assessed 
using a minimum of 9 determinations covering the specified range for the procedures (3 
concentrations/ 3 replicated each). 
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2.7.4  Precision 
Precision measures the degree of repeatability of an analytical method under normal 
operation and is normally expressed as the %RSD for a statistically significant number of 
samples.  According to the ICH, precision should be performed at three different levels: 
repeatability, intermediate precision and reproducibility.  Reproducibility refers to the 
results of collaborative studies between laboratories.  Documentation in support of 
precision studies should include the standard deviation, relative standard deviation, 
coefficient of variation and the confidence interval. 
 
2.7.5  Reproducibility 
Reproducibility expresses the precision within-laboratories variations: different days, 
different analyst and different equipment. 
2.7.6  Limit of detection (LOD) 
The detection limit of an individual analytical procedure is the lowest amount of analyte 
in a sample which can be detected, but not necessarily quantitated as an exact value.  It is 
expressed as a concentration at a specified signal-to-noise ratio, usually two-or three-to-
one.  The ICH has recognized the signal-to-noise ratio convention, but also listed two 
other options to determine LOD: visual non-instrumental methods and a means of 
calculating the LOD.  Visual non-instrumental methods may include LOD determination 
by thin layer chromatography (TLC) or titrations.  Calculations based on the standard 
 
 
 
 
28 
 
deviation of the response (SD) and the slope of the calibration curve (S) at levels 
approximating the LOD according to the formula: LOD= 3.3(SD/S).  The method used to 
determine LOD should be documented and supported and an appropriate number of 
samples should be analyzed at the limit to validate the level. 
 
2.7.7  Limit of quantisation (LOQ) 
Is the lowest concentration of an analyte in a sample that can be determined with 
acceptable precision and accuracy under the stated operational conditions of the method.  
LOQ is expressed as a concentration, with the precision and accuracy of the measurement 
also reported.  A signal-to-noice ratio of ten-to-one is recognized by the ICH as typical.  
The determination of LOQ is a compromise between the concentration and the required 
precision and accuracy.  As the LOQ concentration level decreases, the precision 
increases.  If better precision is required, a higher concentration must be reported for 
LOQ.  This compromise is dictated by the analytical method and its intended use.  The 
same two addition as for LOD can be used to determine LOQ, visual non-instrumental 
methods and a means of calculating the LOQ.  LOQ= 10 (SD/S). 
 
2.7.8  Linearity and range 
Linearity is the ability of the method to elicit test results that are directly proportional to 
analyte concentration within a given range.  It is reported as the variance of the slope of 
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the regression line and is the interval between the upper and lower levels of analyte 
(inclusive) that has been demonstrated to be determined with precision and accuracy.  
The ICH guidelines specify a minimum of five concentration levels, along with certain 
minimum specified ranges.  For assay, the minimum specified range is from 80-120% of 
the target concentration.   
 
2.7.9  Ruggedness 
Is the degree of reproducibility of the results obtained under a variety of conditions 
(including different laboratories, analyst, instruments, reagents, days) expressed as 
%RSD.  In the guidelines on definitions and terminology, the ICH did not address 
ruggedness specifically.  This apparent omission is really a matter of semantics, however,  
ICH chose instead to cover the topic of ruggedness as part of precision. 
 
 
2.7.10  Robustness 
Is the capacity of a method to remain unaffected by small deliberate variations in method 
parameters, such as small changes in organic solvent composition, pH, ionic strength, 
temperature, etc., and determining the effect (if any) on the results of the method.  As per 
ICH guidelines, robustness should be considered early in method development.  If the 
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results are susceptible to variations in method parameters, these parameters should be 
adequately controlled. 
 
2.7.11  System suitability 
According to the USP, system suitability tests are an integral part of chromatographic 
methods.  These tests are used to verify that the resolution and reproducibility of the 
system are adequate for the analysis to be performed.  System suitability tests are based 
on the concept that the equipment, electronics, analytical operations and samples 
constitute an integral system that can be evaluated as a whole.  System suitability is the 
checking of a system to ensure system performance before or during the analysis of 
unknowns.  Parameters such as plate count, tailing factors, resolution and reproducibility 
are determined and compared against the specifications for the method.  These 
parameters are measured during the analysis of a system suitability “sample” that is a 
mixture of main components and expected by-products. 
 
The developed HPLC assay was applied to determine the SU-B levels in two 
commercially available products, viz Phyto Nova Sutherlandia SU1™ tablets and the 
Promune™ capsules. 
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2.8 Commercially available Sutherlandia products 
Several Sutherlandia preparations, made from different raw plant material, mostly the 
dried leaf powder (i.e. leaves and thin stems) are now commercially available in South 
Africa. The Phyto Nova team was the first to make Sutherlandia tablets commercially 
available, by initiating large-scale cultivation and contract manufacturing.  The Phyto 
Nova Sutherlandia SU1™ tablets are marketed as a special chemotype that are made 
from a superior Sutherlandia frutescens variety.  SU1 – a novel plant chemical had been 
isolated and characterized by Phyto Nova and used to breed a specific variety of 
Sutherlandia for large scale farming, a process that has not involved cloning or genetic 
modification.  Sutherlandia plants of the same species may appear identical externally, 
but have major variations in chemical constituents due to genetic, climatic, altitudinal and 
soil factors.  Phyto Nova Sutherlandia SU1™ is the only Sutherlandia that has been 
studied for safety by the Medical Research Council of South Africa in an independent 
safety evaluation in 2002 and the results confirmed the safety of Phyto Nova's 
Sutherlandia SU1™
Recently, a preparation, viz Promune™, containing the freeze dried aqueous extract of 
Sutherlandia, became commercially available in capsule form.  Promune™ capsules are 
manufactured locally by a company called Ferlot Manufacturing and Packaging (PTY) 
Ltd. in Jeffrey’s Bay, South Africa.  Promune™ are presented as a size 2 hard gelatine 
capsule with a dark green cap and a white body containing a grey-white powder with a 
, including haematology, hepatic and renal functions.  The Phyto 
Nova Sutherlandia SU1™ was chosen upon, because it’s the market leader of the dried 
leaf powder solid dosage forms and to test if all the claims made can be justified.   
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characteristic taste, with no imprinting on the capsule.  The manufacturer claimed that 
their product is ‘better’ than the dried leaf powder solid dosage forms as it mimics the 
traditional dosage form (herbal tea).  However, it is not really clear how these two 
products compare, in terms of chemical composition, efficacy and in vivo bioavailability 
of its active constituents.  Figure three presents the two commercially available 
Sutherlandia products of interest viz Phyto Nova Sutherlandia SU1™ and Promune™. 
  
Figure3: Commercially available Sutherlandia products viz Phyto Nova Sutherlandia SU1™ and  
 Promune™ 
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2.9  Effect of elevated temperature and humidity 
Stability testing is the primary tool to assess expiration dating and storage conditions for 
pharmaceutical products.  Many protocols have been used for stability testing, but most 
in the industry are now standardizing on the recommendation of the International 
Conference for Harmonization (ICH).   Stability testing includes long-term studies, where 
the product is stored at room temperature and humidity conditions, as well as accelerated 
studies, where the product is stored under conditions of high heat and humidity.  Stability 
studies are linked to the establishment and assurance of safety, quality and efficacy of the 
drug product from early phase development through the lifecycle of the drug product.  
Stability data for the drug substance are used to determine optimal storage and packaging 
conditions for bulk lots of the material, as well as to determine the expiration date (or 
shelf life).  In order to assess stability, the appropriate physical, chemical, biological and 
microbiological testing must be performed. 
In accelerated environmental conditions, the intrinsic stability and degradation profile of 
the drug substance is evaluated.  HPLC is the predominant tool used to analyze the drug 
substance and the impurities.  The same HPLC method may be used for drug substance 
and drug product, although different sample preparation methods would normally be 
required.  Stress studies at elevated temperature (e.g. 50oC, 60oC and 70oC) for several 
weeks may be performed to assess thermal stability.  Provided the degradation 
mechanism is the same at the different temperature used, kinetic or statistical models can 
be used to determine the rate of degradation at other temperatures (e.g. 25oC).  The solid 
stability should also be performed in the presence and absence of water vapour to assess 
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the dependence of stability on humidity.  Degradation studies should also be performed in 
solutions with pH range 2-9 to assess the impact of solution pH on degradation.  Photo-
stability should also be evaluated.  Oxidation of drug substance under accelerated 
conditions (e.g. hydrogen peroxide) may also be performed to establish oxidation 
products that could be formed and sensitivity to oxidative attack.  According to ICH 
guidance for design of clinical stability studies, the selection of batches, the container 
closure system, specifications, testing frequency and storage conditions, are the most 
important factors to consider.   The container closure system must be evaluated for 
compatibility with the drug substance and drug product to ensure that the container does 
not contribute to degradation or contamination.  The testing frequency represents the 
minimum data required for filing.  It may be advisable to pull and test a one-month 
sample for each storage condition to ensure that the study is proceeding as expected.  
Stability studies are very much interwoven through the entire fabric of the drug product 
life cycle, therefore a detailed knowledge of the stability requirements and the impact on 
other areas (e.g. container closure, process changes) is needed to properly design and 
evaluate stability studies (Microbac Laboratories 2005; ICH Guidelines, 1994; 
www.fda.gov/cder/guidance/cmc3.pdf
 
) 
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2.10 Acid- hydrolysis 
Hydrolysis is a chemical reaction during which one or more water molecules are split into 
hydrogen (H+) and hydroxide ions (OH-) in the process of a chemical mechanism.  The 
addition of an acid serves as a catalyst for the degradation process.  The hydrolysis of 
saponins by a strong acid yields the aglycone form of the saponins.  The breakdown of 
the saponins may indicate the pharmaceutical stability in the GIT (gastric acid) ,and 
hence the effect of acid hydrolysis on the levels of SU-B in the two commercial 
Sutherlandia is also determined (www.fda.gov/cder/guidance/cmc3.pdf). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
 
 
 
 
 
 
 
 
36 
 
CHAPTER THREE 
PLAN OF WORK 
 
3.1  Introduction 
This chapter describes the objectives, hypothesis and study approach proposed for the 
study. 
 
3.2  Objectives 
The objectives of this study were: 
1. to develop a validated stability-indicating HPLC assay for the determination of 
sutherlandioside B present in Sutherlandia plant materials, 
2. to identify and quantify the levels of sutherlandioside B present in a commercially 
available capsule form containing the freeze-dried aqueous extract of the plant 
(Promune™) and one containing the dried leaf powder (Phyto Nova 
Sutherlandia™) and 
3. To determine the effect of elevated temperature and environmental, as well as 
acid hydrolysis, on the stability of the two commercially available products, and 
to determine their pharmaceutical product quality by assessing their levels of 
sutherlandioside B. 
 
3.3  Hypothesis 
It was hypothesized that: 
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1. Sutherlandioside B, based on HPLC peak area ( i.e. SUB peak area > ∑ rest of 
cycloartanol glycoside peak areas) would be the most dominant cyclo-artanol 
glycoside  present in these products,  
2. The Phyto Nova Sutherlandia™ product would have higher levels of 
sutherlandioside B than that in the Promune™ capsules. (i.e. Phyto Nova 
Sutherlandia SU-B concentration > Promune SU-B concentration) and 
3. Elevated environmental temperature and humidity and acid hydrolysis would 
produce a greater decrease in the levels of sutherlandioside B in the dried 
powder tablet product than the aqueous extract containing capsule form(i.e. 
Promune™ t90 elevated conditions > Phyto Nova Sutherlandia™ t90 elevated conditions
 
). 
 
3.4  Study approach 
The above objectives and hypotheses were realized using the following approach: 
 
3.4.1 Selection of Sutherlandia products to test  
 Firstly, several Sutherlandia preparations, made from different plant raw material, are 
commercially available in South Africa.  These commercially available preparations are 
found in various dosage forms including tablets, capsules, traditional tea, gels and 
aqueous infusions and decoction.  Overall, the pharmaceutical quality of all the various 
Sutherlandia dosage forms, including oral solid dosage forms, have however, not yet 
been investigated and consequently, the latter was focussed on in this study.  Secondly, 
Sutherlandia frutescens is currently extensively being researched at the South African 
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Herbal Science and Medicine Institute (SAHSMI), University of the Western Cape 
(ref??)  The focus of this research includes the clinical evaluation of S. frutescens, the 
identification of markers that can be used for quality and efficacy assessments and the 
development of criteria for the evaluation of quality and stability of Sutherlandia herbal 
products.  The program also aims to provide specification guidelines that the South 
African regulatory authority viz the Medicines Control Council (MCC) could use for the 
registration of commercially available Sutherlandia products.  Phyto Nova Sutherlandia 
SU1™ and Promune™ are two such products that may need to be registered. The Phyto 
Nova Sutherlandia SU1™ tablets and Promune™ capsules are both market leaders and 
widely available in South Africa. The former is an example of the dried leaf powder 
dosage forms, which is most widely found in the market, while the other is a freeze-dried 
aqueous extract containing preparation, which more closely resembles the traditionally 
used decoction form.  The results of this study would thus be reflective of the whole 
range of presently available commercial solid oral dosage forms. 
 
3.4.2  Selection of Sutherlandioside B as stability-indicating marker compound 
The major triterpene in commercial Sutherlandia material is a cycloartane-type triterpene 
glycoside called SU1 or Sutherlandioside B.  Sutherlandioside B may be responsible for 
the plant’s anti-cancer activity (Crooks and Rosenthal, 1994; Swaffar, 1995; Rosenthal, 
1997; Bence et al., 2002).  For example the most powerful inhibitory effects in an in vivo 
mouse skin carcinogenesis were found in cycloartanes with hydroxylation at C-24 and 
with a 3-oxo group and this configuration are present in sutherlandioside B.  
Sutherlandioside B  also seems to be easily extractable from plant material, stable in the 
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various plant samples under various processing conditions, and can easily be assayed 
using a simple extraction and HPLC analytical procedure.  Consequently it was selected 
as the stability-indicating marker compound to be used in this study. 
 
 
 
3.4.3  Development and validation of a HPLC assay for Sutherlandioside B.   
The objectives of this study necessitated the quantification of very low concentrations of 
sutherlandioside B in the plant material, thus an HPLC method offered a viable solution.  
Indeed in recent times, HPLC has become the standard method for the analysis of 
triterpenoid glycosides. It yields excellent resolution and reproducible retention times of 
the glycosides that are structurally quite similar (Fu et al., 2000).  It is also a simple 
analytical technique that is quite specific, sensitive and reproducible in compound 
separation when using small sample quantities and can be used with a variety of detection 
methods.  For this study, UV detection was considered because it is readily available, 
cost efficient and amendable for routine quality control use.  HPLC in combination with 
mass spectrometry (MS) can even be used for biological sample analysis and 
identification of breakdown products. All these attributes suggested that HPLC could be 
effectively applied for the present investigation. 
 
3.4.4 Determination of the effect of elevated environmental temperature and 
humidity and acid hydrolysis on the Sutherlandioside B levels in Phyto Nova 
Sutherlandia SU1™ tablets and Promune™ capsules 
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Stability testing is the primary tool used to establish expiry dates and storage conditions 
for pharmaceutical products.  Generally, stability studies are linked to the establishment 
and assurance of safety, quality and efficacy of the drug.  There appeared to be no 
product stability data available to ascertain whether the expiry dates (shelf life) assigned 
for the Phyto Nova Sutherlandia™ tablets and Promune™ capsules were accurate and, 
therefore, the absolute quality of these medicines was unknown.  Normally, the shelf life 
is determined by testing the pharmaceutical stability at ambient conditions over a long 
period (± 2 years) or under stress conditions, such as like elevated environmental 
temperature and humidity over shorter periods (weeks or months).  Because of the limited 
time available and as this is the first investigation on these Sutherlandia products, stress 
testing at elevated environmental temperature (e.g. 400C) and humidity (e.g. 75% RH) 
for several weeks were performed and the levels of sutherlandioside B monitored as 
chemical marker, to ascertain and compare the physiochemical stability of the Phyto 
Nova Sutherlandia SU1™ tablets and Promune™ capsules. The products were also 
subjected to acid hydrolysis to determine the stability of SU-B in an acidic environment 
and to mimic the effect that low pH in the GIT might have on the products...  It was 
expected that the results of the above investigations would provide most valuable 
information on the relative pharmaceutical qualities of the two dosage forms. 
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CHAPTER FOUR 
MATERIALS AND METHODS 
4.1 Introduction 
This chapter reports the chemicals and reagents, equipment and instruments, methods and 
procedures used during the extraction, isolation and preparation of the plant material, the 
identification of the sutherlandioside B (by TLC, HPLC and LC-MS), the HPLC assay 
and, finally, the stability studies. 
 
4.2  Chemicals and reagents 
The following chemicals and reagents were used in the preparation and assay of the plant 
materials and the isolation of the sutherlandioside B. 
• Methanol (analytical grade, AR Saarchem, Merck Chemicals, PTY Ltd) 
• Hexane (analytical grade, AR Saarchem, Merck Chemicals, PTY Ltd) 
• chloroform (analytical grade, AR Saarchem, Merck Chemicals, PTY Ltd) 
• n-butanol (analytical grade, AR Saarchem, Merck Chemicals, PTY Ltd) 
• acetonitrile (HPLC grade, Burdick and Jackson®, USA) 
•  helium gas and nitrogen gas (Afrox Ltd Epping, South Africa) 
• formic acid 99% (analytical grade, KIMIX Chemicals & laboratory 
suppliers, USA) 
• silica gel for column chromatography (40µm, J.T. Baker)  
• TLC silica gel sheets (Alugram Sil G/UV25, Marcherey-Nagel, Germany)  
• vanillin spray   
• distilled water (prepared using a Purite select Analyst HP water 
purification system, England)  
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• The Phyto Nova Sutherlandia SU1™ tablets (containing 300mg of 
Sutherlandia frutescens dried leaf powder) 
• Promune™ capsules (containing 90mg Sutherlandia frutescens freeze-
dried aqueous extract) were purchased from a local health store in Cape 
Town (2009) 
  
 
4.3  Equipment and instruments 
The following equipment and instruments were used. 
 
High Performance Liquid Chromatography (HPLC) System- An Agilent HPLC 
system 1200 series (Hewlett Packard®) consisting of a G1311A Quaternary Pump, a 
G1322A Degasser, a G1315B Diode-array detector and a G1329A Auto Sampler was 
employed.  All the modules were controlled by the Agilent Chemstation software.  The 
column used in this system was the Discovery® HS C18 reverse phase column (USA) 
having 5μm particle size and a column length of 150 × 4.6 mm.   The column was 
equipped with a 2cm LC-18 guard column (Phenomenex, Torrance, CA, USA) 
 
LC-MS System- A Waters API Q-TOF Ultima Instrument equipped with an ESI source 
and an Agilent LC system 1100 series with the following modular components: a HP-
1100 quaternary pump, a vacuum solvent micro degasser, auto sampler and the HP 
ChemStation for LC 3D software were used. 
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Climatic Chamber- a Labcon Humidity Incubator (FSIE-RH20, Labmark®, 
Roodepoort, South Africa) was used and set at 400
 
C and 70% relative humidity (RH). 
 
Other instruments- In addition to the above, the following instruments were also used: 
• Filter unit (Millipore, Cameo 25 AS, DDA 02025So MSI: Micro 
separation INC., USA) 
• centrifuge (Labofuge 200, Germany) 
• vortex (Vortex-2G-560E, Scientific Industries, Inc. Bohemia, N.Y 11716 
USA)  
• micropipette 100μl and 1000μl (Gilson Medical electronics (France). SA) 
• oven (Memmert 854 Schwabach, Germany) 
• balance (Wirsam Scientific & Precision Equipment (PTY) Ltd. Model GA 
110, Germany) 
•  hot plate (Type Rct13 Kg D-79219, Kika-Werke Gmbh&Co., Staufen 
Germany) 
• water bath (Cph110, Lab design Engineering Pty Ltd, South Africa) 
• vacuum filtration system (Supelco, South Africa) 
• vacuum pump (Medi-pump Model 1132-2, Thomas Industries, Inc., USA) 
 
 
 
4.4  EXPERIMENTAL METHODS AND PROCEDURES 
 
4.4.1  Collection and identification of Sutherlandia frutescens plant material 
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In this study, 3 types of Sutherlandia materials i.e. plant raw material and tablet and 
capsule dosage forms were analyzed for sutherlandioside B content and stability using a 
HPLC method.  The Sutherlandia frutescens powdered plant material was obtained from 
Afriplex (PTY) Ltd., Paarl, South Africa in July 2007.  The bulk of the dried leaf powder 
was manufactured into capsules that were used in a clinical study at Karl Bremer 
hospital, Cape Town (Johnson et al., 2007).  The dried leaf powder used in the present 
study was packed into aluminium containers, sealed and stored in a dark cupboard at 
room temperature until further use. 
 
The Phyto Nova Sutherlandia SU1™ tablets and the Promune™ capsules were purchased  
at a local health shop in Paarl, South Africa in the summer of 2008.  The products had an 
expiry date of 31st of December 2010 and were stored at 25o
 
C in a dark cupboard until 
further use. 
 
 
4.4.2  Extraction and isolation of sutherlandioside B 
The method of Fu et al., (2008) was used and adapted to isolate SU-B from Sutherlandia 
frutescens powdered plant material. Briefly, 100g of the dried powder was extracted with 
600mL methanol for 3 consecutive days (600ml ×24hours ×3) at room temperature.  The 
combined extracts were concentrated in vacuo (under 450C) to obtain a dry extract. The 
latter was then suspended in 600ml of purified water and extracted with 400ml hexane 
followed by 300ml chloroform and finally with 300ml n-BuOH (saturated in H2O) 
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sequentially.  The n-BuOH phase was evaporated to dryness in vacuo and the residue 
subjected to silica gel chromatography using a stepwise gradient mixture of 
approximately 200ml of CHCL3/MeOH/H2O (v/v) in ratio 9:1:0, then 6:1:0 and finally 
7:3:0.5 as eluent to give fractions.  The flow rate was set at approximately 10ml per hour 
and fractions were collected every hour.  The total duration of the column 
chromatography was 5 days.  TLC was used to detect the presence of triterpenoids in the 
collected fractions.  For the TLC, mobile phase, consisting of CHCL3: MeOH, ratio 9:1 
was used.  The TLC plates were first viewed under UV at 254 nm and the spots marked 
and then sprayed with vanillin dye, followed by heating on a hot plate to visualize the 
spots.  The column chromatography yielded 140 subfractions.  Subfractions 51-59 were 
combined, evaporated to dryness under a gentle stream of nitrogen gas, reconstituted in 
10ml of methanol and then the solution was subjected to semi-preparative TLC, which 
yielded crystals of the major glycoside, sutherlandioside B.  The isolated sutherlandioside 
B was then subjected to TLC, LC-UV and LCMS analysis to verify its identity as 
described below. 
 
 
4.4.3  Identification of sutherlandioside B by TLC, HPLC and LC-MS methods 
First, TLC was performed on silica gel sheets (Alugram® Sil G/UV254, Macherey-Nagel, 
Germany), for the qualitative determination of sutherlandioside B.  For this, the SU-B 
fraction collected by semi-preparative TLC was reconstituted in a small volume of 
methanol and samples spotted on the plates developed, using mobile phase (CHCL3: 
MeOH, ratio 9:1). The sutherlandioside spot on the plate was visualized by using vanillin 
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spray.  For the latter, 6g of vanillin, was dissolved in 95mL of 96% ethanol, after which 
1.5mL of concentrated sulphuric acid was carefully added to give a clear colourless 
solution.  After elution the TLC plates were allowed to dry and were immediately viewed 
under UV to locate and mark the spots of the analyte.  The plates were then sprayed with 
vanillin stain and heated on a hot plate until coloured spots appeared and the Rf value 
recorded. 
 
Thereafter, qualitative techniques, such as HPLC and LC-MS, were further used for the 
identification of sutherlandioside B.  For identification by HPLC, 10µl of the SU-B 
standard solutions were injected and separated on a Discovery® C-18 column using 
mobile phase 0.1 % formic acid/ acetonitrile (A) and 0.1% formic acid/ distilled H2O (B). 
The column was set at 400C and the mobile phase was pumped at 1ml/ min.  A linear 
gradient was used, starting with 15% (A)/85% (B) to 65% (A)/35% (B) over 20 minutes 
followed by a 5 minute wash with 100% (A) and a 15 minute equilibrium period  with 
15% (A)/85% (B).  Detection was made possible by employing a diodide array (UV) 
detector, set at 260nm and the retention time, peak spectra and peak purity were recorded.  
To establish the retention time for the sutherlandioside B standard, 100μl aliquots of 
standard solutions were injected in triplicate 3 times onto the HPLC column.  The 
retention time of the peak produced was noted and the average and standard deviation 
determined.  To identify the SU B peak in the plant material, the retention times of the 
peaks obtained when plant material was subjected to analysis under similar HPLC 
conditions, (discussed earlier) were compared.  The diode array detector was used to scan 
the UV spectra of the peak of interest in both the standard solution and that of the plant.    
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Furthermore, the plant samples were spiked with SU B to see changes in the height of the 
suspected peak.  
 
 
Thereafter, LC-MS analysis was done to confirm the identity and purity of the isolated 
samples of the SU-B fraction collected. The method involved the use of the [M+H]+ and 
[M+Na]+ ions in the positive and negative ion mode with extractive ion monitoring 
(EIM) and by comparing the MS-data obtained against that reported by Fu et al., (2008).  
The LC-MS analysis was performed on a Waters API Q-TOF Ultima Instrument, 
equipped with an ESI detector.  All acquisitions were performed under positive and 
negative ionization mode with a capillary voltage of 3.5kV.  Nitrogen was used as 
nebulizer gas, as well as the drying gas at 350L/h at a temperature of 3500 
 
C.  Full scan 
mass spectra were acquired from m/z 100- 1990.  Data acquisition and processing were 
done using the Waters API Q-TOF software.  One microliter of the sample (standard 
solution) was injected in the LC-MS system, using a Waters Xbridge C18, 2.1 ×50mm 
column.  The mobile phase consisted of water (A) and acetonitrile (B) at a flow rate of 
0.35ml/ min, with the following gradient elution: 0 - 0.5min 100% A/0% B, then to 0% 
A/ 100% B over 8 min.  Each run was followed by an equilibration period of 7 min with 
100% A/0 % B.  The total run time for analysis was 15 minutes. Peak retention times and 
mass data were obtained from the total ion chromatograms and MS-MS fragmentation 
and analyzed to identify the compound(s) represented by the peaks.  
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4.4.4.  HPLC assay for determination of sutherlandioside B levels in plant 
materials 
 An HPLC assay was developed and validated for the quantitative determination of 
sutherlandioside B in Sutherlandia samples.  
 
 
4.4.4.1. Preparation of standard solutions 
To validate the assay and finally to quantify the levels of SUB in the plant materials and 
products the following standard solutions were prepared. The individual stock solutions 
of standard compounds were prepared by dissolving appropriate amounts of the isolated 
SU-B (see 4.4.2 & 4.4.3) in absolute methanol to obtain final concentration of 330μg/ml.  
The stock solutions were stored, protected against light and refrigerated at -200
 
C, and 
only thawed just prior to use.  Working solutions were prepared by further diluting the 
stock solution with methanol to produce standard solutions at 5 different concentration 
levels over the range of 22-330μg/ml. 
4.4.4.2   General HPLC procedure 
For the separation and quantification of sutherlandioside B, the Agilent HPLC system 
was used with a Discovery® HS C18 HPLC column (15cm× 4.6mm, 5μm, catalog#. 
568522-U)  kept at a constant temperature of 40oC.  The mobile phase consisted of 0.1% 
formic acid-acetonitrile (A) and 0.1% formic acid-distilled water (B) and was pumped at 
a flow rate of 1mL/min.  Separation was performed using the following linear gradient 
elution: 15%A/85%B to 65%A/35%B over 20 min.  Each run included a 5 minutes wash 
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with 100% A and an equilibration period of 15 min with 15% A/85%B.  The eluted peaks 
were detected at wavelengths of 260 and 349nm.   
 
4.4.4.3   Validation of the HPLC assay 
Before the HPLC assay was used, it was validated for separation and specificity, the 
inter- and intra-day variability, quantification and detection limits and linearity.  The 
separation and specificity of the assay were assessed by determining the absence of peaks 
of endogenous compounds interfering with the SU-B peaks in the plant material.  
Accuracy of the method was confirmed by performing a recovery experiment.  A sample 
of Sutherlandia frutescens was spiked with known amounts of the standard compound, 
the spiked sample extracted and the chromatograms obtained analyzed.  To check for the 
intra- and inter-day reproducibility of the assay, five different concentrations of SU B 
were analyzed several times and on different days and the percentage coefficient of 
variation calculated for each individual concentration.  The limit of detection (LOD) and 
limit of quantification (LOQ) were defined at signal-to-noise levels equal to 3 and 10, 
respectively.  The LOD was taken to be the lowest sutherlandioside B concentration, 
which under the described HPLC conditions, produced a peak height at least three times 
higher than the base line noise.  At least three replications were used for each 
concentration.  Lastly, the linearity of the standard curve for SU B was assessed by 
comparing the peak area versus concentration of the standard solution of sutherlandioside 
B (prepared under 4.4.4.1),   Graphpad Prism was used to construct the peak area versus 
concentration of SU-B calibration curve and for the linear regression analysis of the data 
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to give the slope, intercept and correlation coefficient data, which were used to calculate 
the SU-B concentration in each test sample.  
 
 
4.4.4.4  Determination of SU-B levels in Sutherlandia plant raw material, 
Promune™ capsules and Phyto Nova Sutherlandia SU1™ tablets 
To determine the levels of SU B in the test samples, dry plant sample (500 mg) and 
dietary supplements (equivalent to 0.2 and 0.5 g capsule content and tablet weight 
respectively) were added to 5mL of methanol in a 10ml test tube, the latter inverted 10 
times, vortexed for 4 minutes, sonicated for 30 min under ambient temperature and then 
centrifuged for 15 min at 3500 rpm.  Thereafter the supernatant was transferred to a 10 
ml volumetric flask.  Prior to injection, an adequate volume (ca. 2mL) was passed 
through a 0.45 μm nylon membrane filter,  the first 1.0 ml discarded and the remaining 
volume  collected in an HPLC sample vial.  Each sample (dry plant material, Phyto Nova 
Sutherlandia SU1™ methanol solution and the Promune™ methanol solution) was 
injected in triplicate and the injection volume was 10 µl. The amount of SU-B in each 
sample was determined from the standard curve and 3 samples of the analyte (i.e. n=3) 
were assayed and the average amount of SU-B in the dry Sutherlandia leaf powder,  
Promune™ capsules and Phyto Nova Sutherlandia SU1™ tablets were calculated.  
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4.4.5  Determination of the stability of SU-B in Phyto Nova™ tablets and 
Promune™ capsules 
To assess the effect of elevated environmental temperature and humidity on the 
physiochemical stability of the Phyto Nova™ tablets and Promune™ capsules triplicate 
set of each product were  placed (exposed or in container) for 4 weeks in a Labcon 
Humidity Incubator FSIE-RH20, set at a temperature of 400
 
C and a relative humidity of 
70%.  Every second week triplicate samples of the products were moved from the 
climatic chamber.  Each powder sample was extracted with methanol as described in 
section 4.4.4.4, and then immediately assayed for sutherlandioside B content.  Again the 
levels of SU-B in each timed sample were determined from a standard curve that was 
prepared at the same time.  
The sutherlandioside B concentration was calculated and this parameter was used to 
compare these 2 commercially available products.  After assay, the rate of change in the 
SU-B content of the samples over the storage time was determined and compared against 
that which was stored at ambient conditions.  From the degradation profiles, the time for 
10% degradation (i.e. t90
 
 or shelf life) was also calculated and compared to give an 
indication of the stability and hence shelf life of these products.  The rate of degradation 
of the Phyto Nova™ tablets and the Promune™ capsules was compared against each 
other in both the sealed (unexposed) and unsealed (exposed) products and also against 
that stored at ambient conditions. 
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4.4.6 Determination of the stability of SU-B under hydrolytic conditions: Acid-
induced degradation 
To determine the stability of the SU-B under acidic conditions, 2mL of methanol extract 
of plant material, prepared according to procedures described in section 4.4.4.4, was 
refluxed with 2mL of 0.6M HCL.  This solution was heated for 1 hour at 800
     
C in a water 
bath and left to cool overnight.  The next day the solution was filtered and evaporated to 
dryness using a gentle stream of nitrogen gas.  The dried residue was re-suspended in 
2mL methanol, filtered through a 0.45 μm nylon membrane filter.  The first 1.0 mL was 
discarded and the remaining volume was collected in an LC sample vial.  Sample 
solutions were injected in triplicate and subjected to HPLC analysis, as described under 
4.4.4. The effect the acid hydrolysis had on the SU-B, was assessed by comparing the 
amounts of SU-B in acid hydrolyzed samples with that not subjected to such hydrolysis. 
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CHAPTER FIVE 
RESULTS AND DISCUSSION 
 
5.1 Introduction 
In this chapter, the results obtained during the preparation of the S. frutescens material, 
the extraction and isolation of sutherlandioside B, the development and validation of a 
suitable HPLC assay for the analysis of sutherlandioside B,  comparison of the 
sutherlandioside B levels obtained in the two commercially available S. frutescens 
preparations and finally, the determination of the effect of elevated environmental 
temperature and relative humidity, as well as acid hydrolysis on the levels of 
sutherlandioside B in the two products are  reported and discussed. 
 
 
5.2 Collection, extraction and isolation of sutherlandioside B from plant material 
In this project three types of Sutherlandia material were investigated, viz. that of the plant 
and that found in the 2 dosage forms, viz. Phyto Nova SU1™ tablets and the Promune™ 
capsules.  The 2 commercial Sutherlandia products were obtained at a local health shop 
in Cape Town, whereas the S. frutescens plant raw material was purchased from 
Afriplex®, Cape Town.  The company adheres to Good Agricultural Practice (GAP) and 
Hazard Analysis and Critical Control Point (HACCP) standards.  A certificate of analysis 
(Appendix 1) and a voucher specimen was obtained from Afriplex® and further analyses 
were performed at SAHSMI, University of the Western Cape.   The S. frutescens plant 
material was then extracted and subjected to column chromatographic fractionation as per 
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the method of Fu et al. (2008).  When the 100g of dried leaf powder was extracted with 
methanol, 17.3g of a dried dark green methanol extract was obtained (i.e. with a yield of 
17.3%), 1.756g of a dry brown n-BuOH residue  and, eventually, 500mg of the suspected 
major triterpenoid, sutherlandioside B, at a final yield of 0.5%. 
 
 
 
 
5.3 Identification of isolated sutherlandioside B from S. frutescens  
To identify the isolated SU-B, qualitative (TLC) and quantitative (LC-MS and HPLC-
UV) analyses were conducted.  For the TLC, the best separation for the n-BuOH fraction 
was obtained with CHCl3: MeOH [9:1] as mobile phase as depicted below in figure 4B.   
The CHCl3: MeOH [3:2] mixture did not adequately separate the components (broad 
bands, figure 4A) in the n-BuOH fraction and also not the 50:50 mixture (figure 4C), 
where the n-BuOH fraction moved to the solvent front.  Fractions collected from the 
silica gel column chromatography of the n-BuOH residue were thus subjected to this 
TLC using the CHCl3
 
: MeOH [9:1] mobile phase and those having the same TLC 
profiles were combined.  Fractions 51-59, only had one single spot and were combined 
and subjected to semi-preparative TLC and yielded a single spot with a Rf value of 0.5 as 
seen in figure 5.   
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Fig 4:   TLC plates of the n-BuOH fraction of S. frutescens developed under different mobile 
conditions.  Mobile phase consisted of CHCl3
 
:MeOH in ratio: A = 3:2; B = 9:1 and               C 
= 50:50.  For visualization, plates were sprayed with vanillin spray. 
 
                                    
Fig 5:  TLC plate of the isolated sutherlandioside B with mobile phase CHCl3:
 visualize, plates were sprayed with vanillin spray. 
MeOH (9:1).  To  
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The identification of the sutherlandioside B spot, scraped from the TLC plate and 
dissolved in 5ml methanol, was then done by HPLC with a diode array (UV) detector set 
at wavelengths of 349 and 260nm and the results obtained are shown in figures 6 and 7. 
The SU B peak was separated on a Discovery® C-18 column using as mobile phase, 
0.1% formic acid/acetonitrile (A) and 0.1% formic acid/dH2
 
O (B) and a linear gradient, 
starting at 15% (A)/ 85% (B) to 65% (A)/ 35% (B) over 20 minutes, followed by a 5 min 
wash with 100% (A) and an equilibration period (discussed in more detail in section 
4.4.4.2). 
  
 
 
Fig 6:  Representative HPLC chromatogram at 260nm (A),  Peak purity trace or spectrum  (B) and 
UV spectrum (C) of isolated sutherlandioside B standard. HPLC conditions as described in 
4.4.4.2 were used and 10 µl of the 330 ug/ml standard solution was injected. 
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Fig 7:  Representative HPLC chromatogram of isolated sutherlandioside B at 349 nm. 
 
The isolated SU-B had a retention time of 17.821 ±0.02499 minutes (n=6), was pure     
(figure: 6B), had a typical terpenoid spectrophotometric profile (figure: 6C) and was 
more notable and easily detected at 260nm than 349nm (compare figures 6A and 7).  The 
absorbance at 349nm for the isolated SU-B was too low to quantitate and hence 260 nm 
was used for the final HPLC method. 
 
The methanolic solution of the isolated SU B was also subjected to LC-MS analysis and 
in figures 8 and 9 the total ion chromatogram and the MS-MS fragmentation profile for 
the peak at retention time 3.723 minutes are presented. Tables 1 and 2 presents a 
summary of the mass spectra and key-fragment analysis data for the isolated 
sutherlandioside B obtained by LC-ESI-TOF method.  The peak at retention time 3.723 
min. had an exact mass of 652.4186 and the key mass fragments were similar to that 
reported by Fu et al., (Fu et al., 2008) and confirmed the identity of the isolated 
compound as SU B.  
. 
 
 
 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Total ion chromatogram of the isolated SU-B solution using LC-ESI-TOF method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: MS-MS fragmentation profile for peak at retention time 3.723 minutes 
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Table 1:  Mass spectra of sutherlandioside B identified using LC-ESI-MS with positive and  
negative scan mode 
Analyte Mass spectra negative ion 
(m/z) 
Mass spectra positive ion 
(m/z) 
Sutherlandioside B 651.4108 [M-H] 653.4257 [M+H]- 
675.4117 [M+H]
+ 
+ 
 
Table 2: Key-fragment analysis of pure standard compound by LC-ESI-TOF method 
Analyte 
Exact 
Mass 
[M+H] [M+H- + 
Glu]
[M+H- 
+ H2O]
[M+H- 
+ H2O-
glu]
[M+H- 
+ 
2H2O]
[M+H- 
+ 2H2O-glu]
[M+H- 
+ 3H2O]
[M+H- 
+ 3H2
Glu]
O- 
[M+H- 
+ 
4H2
Glu]+ 
O- 
SU B 
652.4186 
653.4265 491.3718 635.4118 473.3631 617.4018 455.3541 599.3913 437.3397 419.32 
 
The isolated SU B was then used to set up the calibration curve and to develop the 
validated HPLC method for the determination of sutherlandioside B in the 2 
commercially available products viz, Phyto Nova™ tablets and the Promune™ capsules.  
 
 
5.4 Development and validation of a HPLC assay for sutherlandioside B in the 
plant material 
 
5.4.1 Development of HPLC assay 
A reverse phase HPLC assay was developed and validated for the quantification of 
sutherlandioside B levels in the Sutherlandia frutescens plant material.  Different HPLC 
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conditions were tested for the separation of the SU B peak from that of other compounds 
found in the chromatograms of both the aqueous extract dosage form and the dried leaf 
dosage form of S.frutescens. First, a Luna® C-18 (150 × 4.60mm,  5μm) analytical 
column was used, but the best separation of the terpenoids in S. frutescens plant material 
was, however, obtained with a Discovery C18 column purchased  from Supelco®.  
Different mobile phases consisting of either methanol or acetonitrile with a mixture of 
different concentrations of acetic acid or formic acid in water, to control pH, were tried to 
optimize the chromatographic conditions.   The best separation was, however, obtained 
when acetonitrile was used as organic phase instead of methanol.  The formic acid was 
added to improve the peak symmetry of the compound and to suppress tailing.  
Therefore, as reported in section 4.4.4.2, the final mobile phase used consisted of a 
mixture of acetonitrile with 0.1% formic acid (A) and H2O with 0.1% formic acid (B) 
with a linear gradient from 15 % (A) at time 0 to 65%(A) over 20 minutes, followed by 5 
minute wash with 100% (A) and a final 10 minute equilibration period with 15% A 
before the next injection.  The mobile phase was pumped at a constant flow rate of 
1ml/min and the column kept at 40o
 
C for the total duration of  the run.. 
5.4.2 Validation of HPLC assay 
The HPLC assay for the analysis of the SU-B levels in the S. frutescens plant material 
and the 2 commercial products was validated for specificity, separation, reproducibility, 
low limit of detection, inter-and intra-day variability and linearity.   
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Examples of a representative chromatogram obtained for the plant material are given in 
figure 10 and that for the isolated SU-B, obtained under similar HPLC conditions 
(described in section 4.4.4.2),  in figure 6.  The SU-B peak in the plant sample was 
symmetrical and had a retention time of 17.828 minutes ± 0.0239(n=6) that was in line 
with the retention time of the isolated SU-B of 17.821 minutes ± 0.02499 (n=6).  The 
plant material sample was also spiked with the pure standard SU-B solution (330µg/ml) 
and then injected onto the HPLC system as described in section 4.4.4.2.  The SU-B peak 
now, as seen in figure 11, had a bigger peak area and height verifying that the peak in the 
plant sample chromatogram was given by SU-B.  Also, the UV spectrophotometric 
profile of the SU-B in the plant material and spiked sample were similar to that in the 
authentic sample.  Together the afore-mentioned findings indicated that the developed 
HPLC method was highly specific, selective and reproducible for the SU-B peak in S. 
frutescens plant material.   
 
The chromatogram of the S. frutescens at 260nm also showed very prominent peaks (esp. 
between 6 to 8 min retention times, see figure 10) that had UV spectra that clearly 
indicated their characteristic flavonoid spectral profile. These peaks most likely were 
those of the sutherlandins A to D that had been identified by Fu et al (2008), but there 
further identification was not pursued in this study.  
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Figure 10: Chromatogram of S. frutescens plant material at 260 nm and the UV spectral and peak 
purity traces of the SU-B at 17.828 min are presented 
 
 
 
 
Figure 11: Chromatogram of S. frutescens plant material spiked with the isolated SU-B standard 
solution at 260 nm and the UV spectral and peak purity traces of the SU-B at 17.821 min are 
presented 
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The results obtained for the validation of the HPLC method are summarized in table 3 
and figure 12.  The five point calibration concentration versus peak area curve for 
sutherlandioside B (figure 12) showed a linear correlation, with r2 
 
>0.9999 ,  over the 
concentration range of 22 to 330 μg/mL (table 3).  The limit of detection (LOD) and limit 
of quantification (LOQ), defined as signal-to-noise ratios  equal to  3 and 10, 
respectively, for the major cycloartanol glycoside were  0.5 and 22 μg/mL, respectively.  
Multiple injections showed that the results were highly reproducible and had  low 
standard error, while the  intra- and inter-day variation of the assay was  lower than 3.0 % 
and the within day CVs for the replicates (n=6)  at two different concentrations (22 and 
55 µg) were 1.23%.  The accuracy of the HPLC method was found to be >97% at all the 
concentration levels for all analyte (Table 3).    
 
 
Table 3:  Summary of validation parameters for the HPLC assay of sutherlandioside B in S. 
frutescens plant material  
            Slope  (mAU/ ug/ml)                    2.967 +/- 0.009261 
 Intercept (mAU)                   -2.703 +/- 1.613 
 Correlation coefficient (r2)         0.9999 
      Intra-day variability (CV%)            0.972% 
 Inter-day variability (CV%)            2.499% 
 Low limit of quantification          22μg 
            Limit of detection                            0.5 μg 
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Table4: Intra-and Inter-day accuracy for SU-B in S. Frutescens. 
 
Analyte 
 
Concentration 
(µg/mL) 
Intra-DAY (n=5) 
Found 
(µg/mL) 
RSD 
(%) 
Accuracy* 
(%) 
 
Inter-Day (n=15) 
Found 
(µg/mL) 
RSD 
(%) 
Accuracy* 
(%) 
 
SU-B 22.0 22.35 1.45 101.4 
 
21.76 1.78 99.04 
 
SU-B 55.0 55.05 0.97 100.1 
 
54.95 1.23 99.9 
 
* Accuracy (%) = 100% x mean of measured concentration/ nominal concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Standard curve of peak area versus concentration of sutherlandioside B levels in S. 
frutescens.  Samples were  subjected to HPLC and detected by UV absorption at 260 nm.  
Each data point  represents mean (+/- SEM) of  3 replications. 
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Overall, the developed HPLC method for the determination of SU-B was found to be 
highly reproducible, specific, selective and accurate and amendable for routine use within 
SU-B concentration range of 22-330 µg/ml. Specifically, it was expected that this assay 
would be suitable for the assay of SU-B in Sutherlandia plant materials and dosage forms 
but would probably not be sensitive enough to use in in vivo bioavailability and 
pharmacokinetic studies. 
  
 
 
 
5.4.4 Comparison of the sutherlandioside B levels in the Phyto Nova™ tablets and 
Promune™ capsules 
 
The developed HPLC assay was then applied to determine how the Phyto Nova™ tablets 
and Promune™ capsules compared in terms of SU-B levels and chromatographic 
profiles.  In addition, the aim of this study was also to determine if SU-B can be used as a 
marker to determine pharmaceutical quality and stability of these products.  
Representative chromatograms obtained for the two products are given in figures 13 and 
14.  The Phyto Nova Sutherlandia™ tablets made from the dried leaf powder had similar 
SU-B levels and chromatographic profiles than the raw S. frutescens plant material.  On 
the other hand the Promune™ capsules had two distinctive extra peaks, viz one at 21.815 
± 0.0321 minutes (n=6) having  a typical terpenoid spectrophotometric profile and one at 
8.291 ± 0.0233 minutes.  Because the extract in the Promune™ capsules is the freeze 
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dried aqueous extract of the same S. frutescens plant material (both the S. frutescens dried 
leaf powder and extract raw materials are supplied by the same manufacturer viz. 
Afriplex®, Paarl, South Africa), the most likely reasons for the presence of the 2 extra 
peaks could be (i) changes caused by the freeze drying process and/or (ii) the presence of 
inactive formulation additives. At this stage the presence of intentionally added active 
adulterants can however also not be excluded.  
 
The SU-B peak was clearly seen in the chromatograms of both commercial products and 
its presence confirmed based on SU-B retention time and spectrometric profile and peak 
purity.  For the Phyto Nova Sutherlandia™ tablet samples the SU-B peak had a retention 
time of 17.825 ± 0.0225 minutes (n=6), the same as the retention time of SU-B in the S. 
frutescens plant material.  For the Promune™ capsule samples the SU-B had a retention 
time of 17.781 ± 0.0421 minutes (n=6). 
 
Generally the SU-B peak in the Phyto Nova Sutherlandia SU1™ tablets was  greater in 
peak area and peak height than that for the Promune™ capsules, in fact the SU-B 
concentration were 1.73 ± 0.013 μg/mg in the Phyto Nova™ tablets compared to an 
average of 1.523 ± 0.016 μg/mg for the Promune™ capsules (table 4).  The 
recommended daily dose for the Phyto Nova Sutherlandia™ tablets is one tablet twice 
daily which is the same as that for the Promune™ capsules, i.e. 1 capsule twice daily. 
However  the Phyto Nova Sutherlandia™ tablets had  a dosage weight of 500 mg per 
tablet (containing 300 mg of S. frutescens plant material) while that for the Promune™ 
capsules was 200 mg per capsule, (containing 90 mg of the freeze dried aqueous extract 
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of S. frutescens ).  Therefore the average dose of SU-B in the Phyto Nova Sutherlandia 
SU1™ tablets was significantly higher than that in the Promune™ capsules (i.e. 1.73  x 
300 mg ± 0.013 vs. 1.523 x 90 mg ± 0.016, respectively; p = 0.05).    
 
Fig 13: Representative HPLC chromatogram and UV spectra of SU-B in the Phyto Nova™ tablets  
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Fig 14: Representative HPLC chromatogram and UV-spectra and purity of the SU-B peak in the 
Promune™ capsules at 260nm. 
 
Clearly both the Phyto Nova Sutherlandia SU1™ tablets and the Promune™ capsules 
contained appreciable amounts of SU-B.  If SU-B was a major contributor to the activity 
of Sutherlandia then the Phyto Nova Sutherlandia SU1™ tablets will, based on the 
results of this study and contrary to the Promune™  manufacturer’s claims, actually be 
significantly more active than the Promune™ capsules on a daily dose basis. The 
presence of SU-B in both these products also strongly suggests that it could be used as a 
marker to determine the stability, shelf-life and pharmaceutical quality of such 
Sutherlandia commercial products.  
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5.5 The effect of elevated environmental temperature and relative humidity on 
the SU B levels in the Phyto Nova™ tablets and Promune™ capsules 
 
The next objective was to determine if the developed HPLC method for sutherlandioside 
B could be used as a stability indicating HPLC assay to determine the pharmaceutical 
quality, like the shelf life of these commercially available S. frutescens products. To 
accomplish this, it had to be ascertained if changes in SU-B levels which rose during  
storage under inappropriate conditions, such as elevated environmental temperature and 
humidity conditions that could lead to product degradation could be discerned with this 
assay. 
 
The results obtained when monitoring SU-B levels, in the  Phyto Nova Sutherlandia 
SU1™ tablets and the Promune™ capsules stored at ambient temperature (25oC) and 
environmental humidity (RH=45%)  and at 40 oC and 70% relative humidity over 4 
weeks are given  in table 5.  The SU-B levels in the two dosage forms stored in sealed 
(i.e. capsule or tablet in air tight container) and unsealed containers (containers with no 
lit) under the 2 sets of conditions were monitored.  The SU-B level in the Phyto Nova™  
tablets stored under ambient conditions were 1.73± 0.013 μg/mg at the start and changed 
minimally over the 4 weeks storage time (i.e. 1.688± 0.009 μg/mg at week 4). The SU-B 
in the tablets stored, both sealed and unsealed, under the elevated conditions (40oC & 
70% RH) however, decreased by 38.27% and 41.68 %, respectively, after 4 weeks of 
storage. Similarly, the SU-B level in the  Promune™ capsules stored under ambient 
conditions at the start was 1.523 ± 0.016 µg/mg, remained almost unchanged at week 4, 
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containing 1.491± 0.012 µg/mg, while that in the capsules stored sealed and unsealed at 
the elevated temperature and humidity conditions decreased significantly by 34.08% and 
35.13%, respectively, over the  weeks storage period.  
 
 
  
 
Table 5: Sutherlandioside B content in the Sutherlandia tablet (Phyto Nova™) and capsule  
 (Promune™) during 4 weeks storage under ambient and elevated temperature and humidity 
conditions.   
 
 
TIME 
SU-B CONCENTRATION IN 
PHYTO NOVA SU1™ ( ug/mg?) 
SU-B CONCENTRATION IN 
PROMUNE™( ug/mg?) 
 
 
Week 
 
Ambient 
Conditions 
Elevated 
conditions 
Sealed 
Elevated 
conditions 
Unsealed 
 
Ambient 
conditions 
Elevated Elevated  
conditions 
 
Unsealed 
Conditions 
Sealed 
0 1.731± 0.013 1.731± 0.013 1.731± 0.013  1.523±0.016 1.523±0.016 1.523±0.016 
2 1.701± 0.011 1.651±0.017    1.455±0.017   1.501±0.014 1.276±0.012  1.264±0.012    
4 1.688± 0.011 1.068±0.010   1.009±0.010   1.491±0.012 1.001±0.011    0.9880.011    
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SU-B CONCENTRATION IN PROMUNE™ CAPSULE
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Figure 15: SU-B concentration in Phyto Nova Sutherlandia SU1™ tablets and Promune™ capsules 
during 4 weeks storage under ambient and elevated temperature and humidity conditions 
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The above mentioned results also suggested, that when Sutherlandia capsules and tablets 
are subjected to elevated temperature and humidity conditions possible degradation 
(indicated by SU-B  loss) is more pronounced when the products are unsealed (i.e. not in 
container).  In addition, the tablets were more sensitive than capsules when subjected to 
these stressful conditions and degraded faster than under elevated temperature and 
humidity conditions (table 5), in both the sealed and unsealed containers over the four 
week period. Reasons to account for the tablets degrading faster that the capsules over a 
period of four weeks, may include the  manufacturing process, packaging material, 
storage, temperature and humidity.  The manufacturing procedures differed from one 
company to another, and this could have impacted on the stability of the tablets and 
capsules.  The Promune™ capsules contained the freeze dried aqueous extract of S. 
frutescens, which involves a freeze-dried process, which is a different manufacturing 
process used compared to that used for the Phyto Nova Sutherlandia™ tablets, which is 
made from the dried leaf powder. 
  
Upon purchase, the expiry dates of the Sutherlandia tablets and capsules were 10/2010 
and 12/2010, respectively, however, the data obtained in this study were insufficient to 
clear if the assigned expiry dates were correct.   The shelf-life of a product is based on its 
storage at ambient temperature over a two year period, however,  accelerated testing is 
usually only done to speed up the process and to identify the breakdown products . 
Accelerated testing is usually done under 3 or more different conditions & then an 
Arrhenius plot is drawn (i.e. graph of temp vs. degradation rate) and extrapolated to get 
the degradation rate for ambient (e.g. 250 C) conditions, and the latter calculated rate 
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value used to predict the shelf-life. Accelerated testing may, however, not work for 
herbals (i.e. it may be problematic to determine the shelf life of herbal products).  
However this issue needs further investigation.     
 
 
Collectively, the results clearly suggests, that while both the  Phyto Nova™ tablets and 
Promune™ capsules may be quite stable under ambient storage conditions, the quality of 
both dosage forms may degrade quite appreciably under elevated environmental 
temperature and humidity. Moreover, the tablets appeared to be more susceptible to 
degradation under the elevated storage conditions than the capsules.  Most important (for 
this study) was, however, the fact that such instability could be indicated using the HPLC 
assay developed in this study.    
 
 
 
5.6 The effect of acid hydrolysis on the SU B levels in the Phyto Nova™ and the 
Promune™ capsules 
 
Sutherlandioside B (SU-B), the focus of this investigation, is the major cycloartanes 
glycoside of Sutherlandia (Fu et al., 2008).  Hydrolytic removal of the sugar moiety (i.e. 
the β-glucopyranosyl moiety at C25) may thus be a possible degradative pathway for this 
potential active constituent of Sutherlandia. Sutherlandia also contain glycosides of other 
terpenoids and flavonoids (Fu et al., 2008 & 2009) and sometimes in assays of such 
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glycosides the samples are subjected to acid hydrolysis to remove the sugar moiety and 
present the respective aglycones. If SU-B is to be a useful marker to monitor the 
pharmaceutical quality of Sutherlandia–containing products, it would thus be important 
to know if SU-B is susceptible to such hydrolytic degradation, and if such a step must be 
avoided in the assay to determine the SU-B levels in Sutherlandia plant material or 
dosage forms. In addition, for SU-B in the Phyto Nova SU1 TM tablets and PromuneTM
 
 
capsule to, as the glycoside, contribute to the in vivo activity of these orally administered 
plant medicinal products, it must (as the glycoside) be stable in the gastrointestinal tract 
and bioavailable (i.e. appreciably absorbed from the gastrointestinal tract into the 
systemic circulation).  
Given the above, the effect of acid hydrolysis on the SU-B levels in the 2 products was 
 thus investigated in this study . To do so solutions of the powder of the Phyto Nova™ 
 tablets (100mg/ml) and of the Promune™ capsule (40mg/mL) were subjected to  
acid hydrolysis using  0.6M HCl at 800 
UV absorption at 260nm (see methods section 4.4.4. and 4.4.6).   
C for 1 hour and the SU-B assayed by HPLC and   
 
 
 
 
 
 
 
 
75 
 
 
Fig. 16: Representative HPLC chromatogram  of an acid-hydrolyzed solution of  the PhytoNova™ 
tablet powder. The effluent was monitored at at 260nm and the SU-B peak expected at 
retention time = 17.825 min was absent. 
 
 
 
 
Fig. 17: Representative HPLC chromatogram of an acid-hydrolyzed solution of  the Promune™     
capsule powder. The effluent was monitored at at 260nm and the SU-B peak expected at 
retention time = 17.781 min was absent. 
 
For both the Phyto Nova™ as well as the Promune™ the SU B peak in essence 
disappeared, as seen in figures 16 and 17, suggesting its complete break down and clearly 
indicating the susceptibility of the SU-B to acid hydrolysis.  From these results it is also 
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very likely that SU-B may not remain intact in the acidic environment in the 
gastrointestinal tract for very long and thus not have high oral bioavailability. In addition, 
when assaying Sutherlandia for SU-B levels, an acid hydrolysis step must be avoided if 
the intact glycoside is to be monitored.  Finally, and more importantly, the results 
obtained indicated that the assay developed in this investigation can indicate SU-B 
degradation (by acid) and can thus be used to monitor Sutherlandia product stability.  
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CHAPTER SIX 
CONCLUSION AND RECOMMENDATIONS 
 
The objectives of this study were, firstly, to develop a validated stability- indicating 
HPLC assay for sutherlandioside B (SU-B), to compare the levels of SU-B  in the dried 
leaf powder dosage form, Phyto Nova Sutherlandia SU1™ tablets and the freezed dried 
aqueous extract dosage form, Promune™ capsules, and thirdly, to determine the effect of 
elevated temperature and humidity as well as acid hydrolysis on the levels of SU-B in 
these commercially available Sutherlandia frutescens products. 
 
From the results, obtained  the following conclusions could be drawn: 
1. A sensitive, reproducible  HPLC assay that could be used to determine 
sutherlandioside B levels in S.frutescens plant raw materials and in  two 
commercially available S. frutescens oral dose products viz.  Phyto Nova 
Sutherlandia™ tablets and the Promune™ capsules, was developed.  The SU-B was 
separated on a Discovery C-18 column, eluted with mobile phase consisting of 
mixture of water/acetonitrile with formic acid and detected by diode array detector set 
at 260nm. The assay was  accurate, precise and reproducible over a SU-B 
concentration range of 22-330µg/ml and had limits of detection (LOD) and 
quantification (LOQ) of  0.5 and 22 ug/ml, respectively. 
 
2.  Both the dried leaf powder dosage form, Phyto Nova Sutherlandia SU1™ and the 
freezed dried aqueous extract, Promune™  contain the major cyclo-artane glycoside, 
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sutherlandioside B.  The Phyto Nova Sutherlandia SU1™ tablets had an average SU-
B concentration of 1.73 ± 0.013 μg/mg and the Promune™ capsules an average of 
1.523 ± 0.016 μg/mg, resulting in the average daily dose of SU-B being ingested 
when taking the Phyto Nova Sutherlandia SU1™ tablets  being significantly higher 
than that for the Promune™ capsules (i.e. 519.0  vs 137.17 μg,  respectively).  Based 
on these results and contrary to the Promune™  manufacturer’s claims, the Phyto 
Nova Sutherlandia SU1™ tablets might, based on SU-B levels, actually be four times 
more active than the Promune™ capsulse on a daily dose basis. 
3. The HPLC profile of potential active constituents of the 2 commercially available 
Sutherlandia containing products i.e.  the dried leaf powder tablet, Phyto Nova 
Sutherlandia SU1™ and the freezed dried aqueous extract containing capsule, 
Promune™  were not the same. The Phyto Nova Sutherlandia™ tablets have 
similiar HPLC fingerprints and SU-B levels than the raw S. frutescens plant 
material, whereas the  Promune™ capsules had two distinctive extra peaks, viz. 
one  at 21.815 ± 0.0321 minutes (n=6) having a typical terpenoid 
spectrophotometric profile and one at 8.291 ± 0.0233 minutes with a 
characteristic flavonoid.spectrophotometric profile, that could be due to the 
freeze-dried process. 
 
4. The sutherlandioside B in commercially available sutherlandia containing solid 
dose preparations are susceptible to degradation under high temperature and 
humidity and acid hydrolysis conditions.  This means. firstly, that SUB should 
thus be a good chemical marker to use to establish the stability and shelf life of 
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such preparations. While the  Phyto Nova™ tablets and Promune™ capsules may 
be quite stable under ambient storage conditions whether accelerated stability 
testing methods can be used to determine shelf-life of sutherlandia herbal 
products is however a still unresolved matter.   Secondly, the susceptibility of 
SUB to acid hydrolysis also indicate that SU-B may not remain intact in the acidic 
environment in the gastrointestinal tract for very long and thus not have high oral 
bioavailability. 
 
5. Finally, the assay developed in this study could indicate SUB breakdown under 
elevated temperature and humdidity  and acidic conditions; it was thus stability 
indicating. 
 
Collectively, the results of this study indicated that the developed HPLC assay for 
sutherlandioside B could be suitable ( can be used) as a stability indicating assay for use 
in the control of the pharmaceutical quality of solid dosage forms (tablets or capsules of 
Sutherlandia. The developed assay is fast, easy to use, sensitive and selective with good 
linearity and amendable for routine use to establish the stability and hence quality of 
commercially available sutherlandia products.  Most important (for this study), was 
however, the fact that such instability (degradation by elevated temperature, humidity and 
acid) could be indicated using the HPLC assay developed in this study and could thus be 
used to monitor Sutherlandia product stability.  This study also provides valuable 
preliminary data on the stability profile of Sutherlandia tablets and capsules that should 
be useful for any future quality control studies on this medicinal plant.   
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In addition to the above conclusions, the following are recommended: 
1. Futher studies are required to determine the acceptable storage conditions for    
these dosage forms of Sutherlandia, e.g. container specifications, hydroscopicity 
of the material, sensitivity to light etc. 
2. Aspects regarding the shelf life of these products also need to be pursued to 
determine the correct expiry dates  
3. The effect of medium (e.g pH, surfactants) on the SU-B levels in S. frutescens 
plant material.  
4. Determination of bioequivalence of these two products. 
 
 
Overall, the results of this study provide valuable information about SU-B as marker 
compound for the determination of the pharmaceutical stability and the effect of stress 
conditions on the stability and pharmaceutical qualities of these commercially available 
herbal products. 
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